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Introduction and objectives 
 
 
Organic chemistry has always turned great attention to the synthesis of bioactive 
natural products both to determine their structure and to understand their chemical and 
biological behaviour or to supply greater amounts of those compounds whose natural 
occurrence is no sufficient. A particular interest concerns the synthesis of plant derived 
natural products, since many medicinal drugs belong to this class of compounds 1a. 
Since most natural products are chiral, their obtaining in enantiopure form represents a 
further challenge for the organic chemist. 
 
 
1.1. Terpenes 
 
The term terpenes originates from turpentine (lat. balsanum terebinthinae). 
Turpentine, the so-called “resin of pine trees”, is the viscous pleasantly smelling balsam 
which flows upon cutting or carving the bark and the new wood of several pine tree 
species (Pinaceae). Turpentine contains the “resin acids” and some hydrocarbons, 
which were originally referred to as terpenes. Traditionally, all natural compound built 
up from isoprene subunits and for the most part originating from plants are denoted as 
terpenes.  
Terpenoids constitute a wide family of natural compounds structurally different from 
each other, deriving from isoprene units linked to each other from head-to-tail. Typical 
structures have carbon skeletons built up from (C5)n units and are classified as 
Hemiterpens (C5), Monoterpens (C10), Sesquiterpens (C15), Diterpens (C20), 
Sesterterpens (C25), Triterpens (C30), Tetraterpens (C40) and Polyterpens (C5)n (Figure 
1). 
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Figure 1: Examples of Terpens 
 
 These diterpenoids display a wide range of biological activities against cancer, 
malaria, inflammations and a variety of infections disease (viral and bacterial). 
 Isoprene is naturally produced, however, is not involved in the biogenesis of these 
compounds; have been identified, instead, as biologically active isoprene units, the 
diphosphate ester: dimethylallyldiphosphate (DMAPP) and isopentil diphosphate (IPP). 
 In Nature, terpenes occur predominantly as hydrocarbons, alcohols and their 
glycosides, ethers, aldehydes, ketones, carboxylic acids and esters. Terpenoids of 
different sizes and compositions are found throughout all classes of organisms; in fact 
Terpenoids represent the largest group of natural compounds, with over 35,000 are 
known in the literature. 
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Figure 2: Common terpenoids. 
 
Various complex terpenoids have biological activities and are used for the treatment 
of human disease. Many of them are essential components of human metabolism, such 
as cortisone and testosterone, the membrane component cholesterol, and the lipid 
soluble vitamins A, E, and K (Figure 2). Different terpenoids are involved in plants, 
fungi, bacteria, and insects secondary metabolism, leading to organisms prosperity in 
their specific environments. Terpenoids have always provided many lead compounds in 
disparate fields, such as the pharmaceutical and the agricultural ones. Among these 
pharmaceuticals, the anticancer drug Paclitaxel and the antimalarial drug Artemisinin 
are two of the most renowned terpene based-drug.  
Paclitaxel or Taxol (Figure 3), is an important anticancer agent with a broad 
spectrum of activity against some forms of cancer that do not respond to other 
pharmaceutical remedies. It was isolated and identified from the bark of the Pacific yew 
(Taxus brevifolia) more than 35 years ago1b. Its total synthesis1c currently is not 
economically feasible because of the challenges of stereochemistry, low yield and high 
cost; α-Santonin (Figure 3) is one of the major anti-helminthic components of plants 
from Artemisia species, and it is effective for roundworm treatment. Artemisinin, 
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produced by the plant Artemisia annua, is a functionalized sesquiterpene active against 
malaria, including the quinine derivatives resistant strains; α-pyrethrins derived from 
Chrysanthemum cinerariifolium have potent insecticide activity. For this reason the 
extracts of Chrysanthemum cinerariifolium are used as biodegradable insecticides for 
agricultural applications. Pyrethrin are neurotoxins that attack the nervous systems of all 
insects. When present in amounts not fatal to insects, they still appear to have an insect 
repellent effect. 
The sweet terpene glycoside stevioside, which is a natural sweetener extracted from 
the leaves of Stevia rebaudiana Bertoni, is responsible for the sweet taste of the leaves 
and it is used as a sweetener by the Center and South American indigenous peoples. 
 The smaller, more volatile terpenes are often used in flavours and perfumes. 
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Figure 3: Terpenoids used in various practical applications. 
 
Terpene biosynthesis is usually carried out by joining carbon atoms by electrophilic 
condensations and cyclizations. Specific enzymes known as prenyltransferases 
condense isoprene units, giving rise to polyprenyl diphosphates geranyl diphosphate 
(GPP), farnesyl diphosphate (FPP), and geranylgeranyl diphosphate (GGPP), as 
reported in scheme 1. In the condensation reactions, dimethylallyl diphosphate 
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(DMAPP) loses diphosphate, and the resultant allylic carbocation is attacked by the 
nucleophilic double bond of isopentenyl diphosphate (IPP), with formation of GPP for 
the subsequent proton loss. In FPP and GGPP syntheses, additional IPP molecules are 
added in a similar fashion until the proper chain length is attained. 
Cyclization of acyclic terpenoid substrates typically proceeds through several 
carbocationic intermediates, which readily undergo remarkable structural 
rearrangements. Specific enzymes named terpene cyclases, whose substrates are GPP, 
FPP, and GGPP, control these reactions providing a stereochemical template for 
cyclization and rearrangement. Larger terpenes can be generated by further 
condensations of these prenyl groups. The wide variety of arrangements of these linear 
and cyclic moieties results in the incredible structural diversity of terpenoid carbon 
skeletons observed in Nature. 
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Scheme 1: Biosynthesis of terpenes.  
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1.1.1. Diterpenes 
 
Diterpenes, composed of four isoprene units (20 carbon atom), are well known for 
their biological activities in many complex species. They are universally present in 
small amounts in living organisms, where they play numerous vital roles in plant 
physiology as well as important functions in all cellular membranes. They are the most 
widely distributed terpenes in the plant kingdom and it is shown that the extraordinary 
variety they display can be due to ecological factors playing an evolutionary role2a. As 
shown in Figure 4, diterpene compounds possess a great structural variety.  
Phytol, one of the most simple diterpenes, is an acyclic diterpene alcohol that can be 
used as a precursor for the synthetis of vitamin E2a and vitamin K.2c; geranylgeraniol, 
another diterpene alcohol which plays a role in several important biological processes. 
In fact it is an intermediate in the biosynthesis of other diterpenes, of vitamins E and K2d 
and it also used in the post-translational modification known as geranylgeranylation. 
Geranylgeraniol is a pheromone for bumblebees and a variety of other insects2e.  
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Figure 4: Common diterpenes. 
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Vitamin A1 (Figure 2), vitamin A2, and cembrene (Figure 4) are monocyclic 
diterpenes, the last of which belongs to a very wide variety of other natural products 
found both in plants and in animals2f and marine organisms. It was isolated from corals 
of the genus Nephthea2g. Sclareol (Figure 4), a bicyclic diterpenoid, is an important 
starting material for the preparation of perfumery chemicals. It is also able to kill human 
leukemic cells and colon cancer cells by apoptosis2h,2i.  
Resin acids (such as abietic and pimaric acids) are important constituents of tricyclic 
diterpenes: they are the major components of the oleoresin synthesized by grand fir 
(Abies grandis) as a defensive secretion against insect and pathogen agents attack. The 
tetracyclic diterpenes kaurane and gibberellic acid, constituents of a class that counts 
more than 100 different structures, play a significant role as plant growth hormones. 
Several diterpenes show significant pharmacological activities, such as for example 
antitumor, anti HIV, antioxidant, analgesic, and neuroprotective ones, giving rise to a 
great pharmacological interest toward this class of natural products. The tetracyclic 
diterpenes ent-15-oxo-kaur-16-en-19-oic acids 32a-c, isolated from Chrysobalanus 
icaco L. subsp. atacorensis (A. Chev.) F. White (Chrysobalanaceae family), showed in 
vitro activity in the NCI’s anti-HIV screen3, while the tricyclic diterpenes from the 
cones of Sequoia sempervirens genus (20-hydroxyferruginol derivatives 33a-e) have 
been demonstrated to possess antitumor properties4 (Figure 5). 
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Figure 5: Chrysobalanus icaco L. subsp. atacorensis (A. Chev.) F. White and Sequoia sempervirens 
genus diterpenes. 
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Several diterpenes isolated from plants of the genus Salvia, especially from Salvia 
miltiorrhiza, showed other interesting pharmacological properties, such as antioxidant, 
antimicrobial, antiinflammatory, analgesic, antipyretic, hemostatic, hypoglycaemic, and 
antitumor5. The antibacterial, antitumor, antioxidant, antimutagenic, antiinflammatory 
and antiplatelet aggregation activities are attributed to the presence of the tanshinones 
diterpenes6 (Figure 6). Recently, Mohsen Imanshahidi and Hossein Hosseinzadeh have 
examined important pharmacological effects on the central nervous system of several 
diterpenes isolated from different species belonging to the genus of Salvia, among 
which sedative, hypnotic, hallucinogenic, skeletal muscle relaxant, analgesic, memory 
enhancing, anticonvulsant, neuroprotective and antiparkinsonian activities, as well as 
the inhibition of ethanol and morphine withdrawal syndrome7. 
 
O
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Cryptotanshinone  
 
Figure 6: Some of the more than 30 kinds of tanshinones from the genus Salvia miltiorrhiza. 
 
One of the most well known medicinally valuable terpenes is the diterpene, taxol. 
Taxol was first isolated from the bark of the Pacific yew (Taxus brevifolia) in the early 
1960’s, but it was not until the late 1980’s that its value as an anticancer drug was 
determinate. It acts to stabilize the mitotic apparatus in cell, causing them to act as 
normal cells rather than undergo rapid proliferation as they do in cancer. 
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1.2.  Stemarane diterpenes 
 
Stemarane diterpenes are tetracyclic compounds characterized by a particular 
hydrocarbon skeleton named “stemarane skeleton” (Figure 7). The archetype of this 
class of compounds, Stemarin 338 (Figure 8), was isolated in 1975 by Manchand and 
Blount from a rare littoral plant of the West Indies, belongs to the family of 
Scrophulariaceae
9, the Stemodia Maritima L (Figure 9). This plant is known in Jamaica 
as “poor man’s strength”, because in the Caribbean island of Curaçao extracts of its 
leaves are reputed to be a treatment for venereal disease10.  
The Stemodia Maritima L yielded several diterpenes, other than stemarin 33, with 
mild cytotoxic activity: stemodin 34 and stemodinone 3511, 2-deoxystemodinone 3612, 
and maritimol 3713 (Figure 8). These diterpenes are structurally similar to the fungal 
metabolite aphidicolin 3814, another tetracyclic diterpene, isolated from the fungus 
Cephalosporium aphidicola, which shows various pharmacological activities including 
antiviral 15 and antitumor16 ones. 
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Figure 7: Carbon-skeleton of stemarane diterpenes. 
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Figure 8: Stemarane, stemodane, and aphidicolane diterpenes. 
 
Stemarane diterpenes are mainly found in plants, where they show several important 
roles such as defensive properties, and resistance to diseases caused by fungi and 
bacteria. 
 
     
 
Figure 9: Stemodia maritima L. (left) and schematic representation of the Calceolaria genus (right). 
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Figure 10: Structures of the stemarane diterpene: Stemarin 33, Oryzalexin S 39, and Stemar-13-ene 
40. 
 
The plant Oryza Sativa L., belonging to the Poaceae family17, produces an important 
stemarane diterpenes, the phytoalexin oryzalexin S 39, whose synthesis induction is 
stimulated by the pathogen attack of the rice blast fungus Pyricularia oryzae Cav. (the 
teleomorph is named Magnaporthe grisea), or by irradiation with UV-ray or treatment 
with heavy metals (Hg, Cu)(Figure 11). As mentioned before, Oryzalexin S 39 (Figure 
10) was isolated in 1992 by Kodama and coworkers17 by UV irradiation of the plant 
Oryza sativa L. 
 
    
Figure 11: Oryza sativa L., rice plant and Magnaporthe grisea infected leaves. 
 
In 2001 Oikawa and coworkers reported the isolation of stemar-13-ene 4018 (Figure 
10) from the phytopathogenic fungus Phoma betae (Figure 12), and it is the only 
diterpene present in the fungi reign. The phytopathogenic fungus Phoma betae19 also 
produces aphidicolin 38 together with less oxidized intermediates20. This co-occurrence 
of diterpenes in the Phoma betae fungus is especially noteworthy not only from a 
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biosynthetic point of view but also because stemarane diterpenes were found previously 
only in plants. 
 
       
Figure 12: Fungus Phoma betae, (left) microscopic view and (right) naked-eye. 
 
Stemarane diterpenes are also found in plants from the Calceolaria genus belonging 
to the Scrophulariaceae family (Calceolaria Lepida21, Calceolaria Latifolia22, 
Calceolaria Kingii Phil.23, Calceolaria Polifolia24, Calceolaria Glabrata25, and 
Calceolaria Dentata
26)(Figure 13). The Calceolaria is one of the most abundant genus 
in the Scrophulariaceae family. There are more than 500 species distributed throughout 
New Zealand and especially Central and South America27; 86 species grow in Chile28, 
which are used sometimes in popular medicine as stomach tonics, bactericidal agents 
and sweeteners. 
 
      
Figure 13: Calceolaria Polifolia (left) and Calceolaria Dentata (right). 
 
Several stemarane diterpenes was isolated by Garbarino and coworkers from Chilean 
plants of the Calceolaria genus (Universidad Tecnica Federico Santa Maria, Valparaiso, 
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Chile) (Figure 14). In particular, from a plant that grows in the coastal hills of central 
Chile, Calceolaria Lepida, Garbarino and coll.21 isolated two new stemarane diterpenes: 
ent-stemar-13(14)-en-19-oic acid 41 and ent-stemar-13(14)-en-19-ol 42 (Figure 14). 
The last compound was also isolated from a plant that grows on hills of north and 
central Chile, Calceolaria Latifolia Benth.22, and from a species which grows on the 
coastal hills of central Chile, Calceolaria Polifolia24 (Figure 13). Furthermore, during 
these studies, has been reported the isolation and characterization of three new 
stemarane derivatives: 19-malonyloxy-ent-stemar-13(14)-ene 43 and 17-acetoxy-19-
malonyloxy-ent-stemar-13(14)-ene 44 from Calceolaria Polifolia24 and ent-stemar-
13(14)-en-18-ol 45 from Calceolaria Latifolia22. From a plant which grows in north and 
central Chile, Calceolaria Kingii Phil., ent-stemara-13(14)-en-17-acetoxy-18-ol 46 has 
been isolated and then structurally elucidated23. From a perennial plant which grows in 
the middle-South of Chile, Calceolaria Dentata (Figure 14), 2-acetoxy-13-methylene-
stemarane 47 and 7-malonyloxy-13-methylene-stemarane 48 were isolated and then 
structurally elucidated by spectroscopic analyses26. In the same way, from Calceolaria 
Glabrata, a shrub common in the southern part of Chile, the diterpene 13-methylene-7-
acetoxy-stemarane 49 was isolated and then structurally elucidated25. 
H
H
42 R = CH2OH
41 R = COOH
R
H
H
CH2OCOCH2CO2H
43 R = CH2OH
44 R = COOH
CH2R
H
H
HOH2C
45 R = OH
46 R = OAc
47 R1 = OCOMe, R2 = H
48 R1 = H, R2 = OCOCH2CO2H
R1
R2 OAcH
H
49
 
Figure 14: Stemarane diterpenes isolated by Garbarino and coworkers. 
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1.2.1. Structure of stemarane diterpenes 
 
The stemarane diterpenes carbon skeleton is reported in Figure 15, and its main 
structural characteristics are reported below: 
• the bicyclic system C/D is constituted by a bicyclo[3.2.1]octane fused to the 
bicyclic A/B system in a different fashion with respect to other tetracyclic 
diterpenes possessing the bicyclo[3.2.1]octane system; 
• oxygenated functions can be present at C(2), C(7), C(13), C(17), C(18), and 
C(19);  
• two contiguous quaternary carbon atoms, the C(9) and C(10), are present, the 
former being a spirocyclic atom. 
18
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Figure 15: Stemarane diterpenes carbon skeleton 
Only in the case of stemarin 33 the absolute configuration was determined by X-ray 
crystallographic analysis8. In particular, its absolute stereochemistry was determined 
through X-ray crystallographic analysis of its tosylate 33a (Figure 16-17). 
OH
H
H
RO
H
H
HO
HO
33   R = H
33a R = SO2C6H4Me-p
39
 
Figure 16: Structures of Stemarin 33, its tosylate 33a, and Oryzalexin S 39. 
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Figure 17: ORTEP drawing of stemarin tosylate 1a, image from P. S. Manchand, J. F. Blount, 1975, 
J. Chem. Soc., Chem. Commun., 894). 
 
On the contrary, oryzalexin S 39 absolute structure by means of crystallographic data 
is not available. The relative configuration of oryzalexin S 39 was established by a 
series of 2D-NMR experiments (13C-1H COSY, 1H-1H COSY, 13C-1H HOHAHA, 13C-
1H COLOC and NOESY)29, confirming the relative three-dimensional relationships 
between the functional groups (Figures 2.12-2.13).  
 
 
 
Figure 18: Structure of oryzalexin S, 
13
C-
1
H COLOC data (image from S. Tamogami, M. Mitani, O. 
Kodama, T. Akatsuka, 1993, Tetrahedron, 49, 2025). 
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Figure 19: Structure of oryzalexin S, NOESY data (image from S. Tamogami, M. Mitani, O. 
Kodama, T. Akatsuka, 1993, Tetrahedron, 49, 2025). 
 
 
1.2.2. Biogenesis of stemarane diterpenes 
 
Stemarane diterpenes biogenesis was deeply studied in the past years particularly in 
rice plants, since rice provides a model system to investigate labdane-related 
diterpenoid biosynthesis, as this genomically characterized plant30 produces a number of 
such natural products, many of which are terpenoids (this class of compounds 
comprises, as discussed above, the largest class of natural products with nearly 30000 
known members31, among which labdane-related diterpenoids constitute over 10% of all 
of them).  
As shown in scheme 2, rice became a model system for investigating the labdane-
related diterpenoids metabolism. Biosynthesis of labdane-related diterpenoids is 
characterized by two subsequent cyclizations (route A and route B), catalyzed, 
respectively, by class II and class I terpene synthases. 
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Scheme 2: Known cyclization steps in rice. The corresponding enzymes are indicated, together with 
their products and the derived natural products. 
 
In addition to the ubiquitous gibberellic acid phytohormones, rice produces more 
than 10 other labdane-related diterpenoids, which serve as phytoalexins32,17, antibiotic 
compounds produced in response to microbial infection33, and allelochemicals34, 
secreted from the roots to suppress germination of neighbouring seeds35. The known 
rice diterpenoids fall into five structurally related families: momilactones A and B, 
phytocassanes A-E, gibberellins, oryzalexins A-F, and oryzalexin S 39. They are 
polycyclic diterpenes characterized, respectively, by five different structures: syn-
pimara-7,15-diene, ent-sandaracopimara-8(14),15-diene, ent-cassa-12,15-diene, ent-
kaurene, and syn-stemar-13-ene, which is the stemarane diterpenes biogenetic 
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precursor36. Class II diterpene cyclases produce specific stereoisomers of 
labdanienyl/copalyl diphosphate (CPP)* from the universal diterpenoid precursor 
(E,E,E)-geranylgeranyl diphosphate (GGPP)37. This bicyclic core structure can then be 
further cyclised and/or rearranged by more typical (i.e., class I) CPP stereospecic 
terpene synthases to form various skeletal structures38. While prototypical plant class I 
terpene synthases contain two structurally defined domains39, those involved in labdane-
related diterpenoid metabolism invariably contain an additional N-terminal sequence 
(>>240 amino acids) termed the ‘insertional’ element40.  
However, whereas the class II cyclases contain a DXDD motif required for their 
protonation-initiated cyclization reactions41, the class I enzymes contain a separately 
placed DDXXD motif, which is involved in the ligation of the divalent metal ion 
binding, required for the corresponding diphosphate ionization initiated reaction42. From 
the known sequence information available for rice, four class II and ten class I labdane-
related diterpene synthases have been predicted. The class II genes were termed 
OsCPS1–443, and all the active class II enzymes produce CPP. Specifically, OsCPS1 
and OsCPS2 produce ent-CPP for gibberellins, phytocassanes, and oryzalexins A-F 
biosynthesis, respectively, while OsCPS4 produces syn-CPP, and OsCPS3 is a pseudo-
gene44.  
The class I genes were assigned as OsKS1-1043,45, and only OsKS1 actually operates 
in gibberellin biosynthesis and, presumably, produces ent-kaurene. The synthases 
responsible for production of ent-cassa-12,15-diene, synpimara-7,15-diene, and syn-
stemar-13-ene have also been termed OsDTC1, OsDTS2, and OsDTC2, 
respectively40,46. To avoid confusion, it was suggested30c for these non-kaurene 
producing class I genes the use of OsKSL (rice kaurene synthase-like), with the 
corresponding number from Sakamoto et al. (2004)43, where appropriate. Thus, OsKS1 
presumably produces ent-kaurene43,47, OsKSL4 (OsDTS2) produces syn-
pimaradiene40,45, OsKSL7 (OsDTC1) produces ent-cassadiene46a, OsKSL8 (OsDTC2) 
produces syn-stemarene46b, and OsKSL10 produces ent-sandaracopimaradiene45 
                                               
* Abbreviations used: CPP, copalyl diphosphate; GC, gas chromatography; GGPP, (E,E,E)-
geranylgeranyl diphosphate; KS, kaurene synthase; MS, mass spectrometry; NMR, nuclear magnetic 
resonance; OsCPS, rice CPP synthase; OsKSL, rice kaurene synthase-like; RT-PCR, reverse-transcription 
polymerase chain reaction; RACE, rapid amplification of cDNA ends. 
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(Scheme 2). The different conformations that the universal diterpenoid precursor 
(E,E,E)-geranylgeranyl diphosphate (GGPP) can assume bring to different products in 
the first cyclization (Scheme 3, route A). Therefore, while the chair-chair conformation 
leads to the formation of ent-copalyl diphosphate, the chair-boat conformation leads to 
the formation of syn- copalyl diphosphate, also known as 9β-labdadienyl diphosphate 
for the beta orientation of H-C(9).  
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Scheme 3, route A: enzymatic cyclization of (E,E,E)-GGPP. 
 
Diterpenes possessing a unique bicyclooctane skeleton in the C/D ring are divided 
into two classes: C9-ethano-bridged diterpenes (C9EBD) and C8-ethano-bridged 
diterpenes (C8EBD). C9EBD include compounds such as stemodin 34, stemarin 33 and 
aphidicolin 38 (Scheme 4), whereas beyerane, kaurene, atisirene and trachylobane 
belong to C8EBD (Scheme 5). The cyclization route B would convert ent-copalyl 
diphosphate III and syn-copalyl diphosphate I into, respectively, transient pimarenyl 
intermediates IV and II, which after a series of rearrangements and proton shifts might 
form the diterpenes belonging to the two classes (Scheme 414b,48 and Scheme 549, 
respectively). As shown in scheme 4, aphidicolane, stemarane and stemodane skeletons 
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might derive from the same biogenetic pathway via compound 20. The isolation of 
stemar-13-ene 40 in fungus Phoma betae18 together with other biogenetic precursors of 
aphidicolin 38 confirms the above biosynthetic route. The proposed biogenetic pathway 
for oryzalexin S 3929 supports the idea that stemar-13-ene 40 is the probable 
hydrocarbon precursor of the stemarane phytoalexin; extracts of chitin-treated rice cells 
actually catalyze the biosynthesis of stemar-13-ene 40 from 9β−labdadienyl 
diphosphate I30c. 
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Scheme 4, route B: biosynthetic pathway to C9-ethano-bridged diterpenes. 
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Scheme 5, route B: biosynthetic pathway to C8-ethano-bridged diterpenes. 
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1.2.3. Previous synthesis of stemarane diterpenes  
 
The first synthesis of a stemarane diterpene was reported in 1980 by Kelly and co-
workers at the University of New Brunswick67 who obtained  stemarin 33 using as an 
intermediate tricyclic compound, previously synthesized by Spencer et al.68 in racemic 
form in the course of the synthesis of the deisopropyldehydroabietic acid (scheme 6). 
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Scheme 6: Synthesis of (±)-stemarin 33. 
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The approach followed by Kelly is based on the method of photochemical annulation 
of Wiesner69 and on the transposition of bicyclo [2.2.2] octane systems to bicyclo 
[3.2.1] octane systems70 (Scheme 8). 
According to the synthesis of Kelly, the diketone III, synthesized according to the 
known procedure of Robinson annulation71, starting from 2-methyl-1,3-cycloesandione, 
it was selectively reduced to give the alcohol IV, according to the procedure of Boyce 
and Whitehurst72 slightly modified from Spencer73. The compound V was obtained by 
reaction of the alcohol IV74 with HCl and dihydropyran in dichloromethane. The next 
step was a "reductive carboxymethylation" of V, according to the methodology of 
Stork75, that is a procedure that involves treatment with Li in liquid NH3, followed by 
carbonation, acidification, and esterification with diazomethane. In particular, Spencer’s 
procedure, which consists in the separation of the product of carbonation before 
acidification and subsequent esterification, has allowed to isolate directly the 
tetrahydropyranyl ether VI, which was then methylated to give VII. The compound VII 
is the majority product of the methylation β-ketoester VI, which is controlled 
stereoelettronically76 in the reaction site by 1,3-diaxyal unfavorable interactions (by the 
β-methyl substituent, and two hydrogens 2β and 6β). In this conversion, in fact, in 
addition to β-methylation, which leads to an intermediate which has the stereochemistry 
of the abietic acid, the α-methylation was obtained, used by Spencer for the synthesis of 
podocarpic acid77. The conversion of VII to IX was achieved through the removal of 
the carbonyl group at C(3) (using Raney-Ni desulfurization with the corresponding 
thioacetal) and the subsequent oxidation of the alcohol group at C(9) with the Jones 
reagent78.  
The formylation of the intermediate X and Robinson annulation led to the tricyclic 
enone XII, which was converted first by photochemical addition of allene and after by 
methylation to give methylencyclobutane XIII. After protection of the carbonyl group, 
the methylene group was subjected to oxidative cleaved, and the new carbonyl group 
XIV was quantitatively reduced to XV. By treatment of XV with diluted mineral acid, 
the deprotection of the carbonyl group was obtained, followed by a retroaldolic 
reaction, which was followed by a new aldol-condensation, leading to the formation of 
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the chetolo XVIa (in a ratio 3:1) and its epimer XVIb  (differentiated by the different 
orientation of the hydroxyl group ) (Scheme 7) . 
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Scheme 7 : Intramolecular aldol condensation. 
 
Only the second epimer has the hydroxyl group oriented correctly for the subsequent 
transposition to stemaranic system (Scheme 8). 
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Schema 8 : Solvolitic rearrangement. 
 
The deoxygenation of compound XVIb led to alcohol XVII, from which, by means 
of the solvolitic rearrangement reaction of its tosylate XVIII, the compound XIX was 
obtained. The conversion of XIX into stemarin 33 was obtained by stereoselective 
epoxydation and subsequent reduction of the ester group to a primary alcohol and by the 
reduction of the epoxide to tertiary alcohol. 
This synthesis has a weaknesses: as can be seen in scheme 6, the aldol condensation 
gives two products: the epimer XVIa, in which the hydroxyl group is endo, and the 
other epimer XVIb in which the hydroxyl group is exo (in a ratio 3:1). Only the 
minority epimer has the HO-C(12) correctly oriented for subsequent rearrangement 
reaction to stemaranic system. The solvolitic rearrangement, in fact, is characterized by 
stereoelectronic requirements: the bond that migrates is the antiperiplanar bond regard 
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the leaving group (Scheme 7). the synthesis of Kelly proceeds only with the minor 
epimer of the aldol condensation (XVIb) and this entails a serious loss of efficiency. 
 
The second synthesis of a stemarane compound, stemar-13-ene 40, was acheved in 
the laboratory where I’ve done this PhD thesis (Scheme 9). This summary is born from 
the need to overcome the difficulties encountered by Kelly in obtaining key 
intermediate bicyclo [2.2.2]-2-eightyolico. 
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Schema 9 : Synthesis of (+)-stemar-13-ene 40. 
 
The starting material was the natural product (+)-podocarpic acid, which was 
converted into desired enone XXV according to the methodology of Wenkert79, which 
 
INTRODUCTION AND OBJECTIVES 
 
26 
 
provides the methylation of phenol group and the acid group to give homologous 
anisole esterified80, the reduction of the carboxylic group with LiAlH4
81, the oxidation 
of primary aliphatic hydroxyl group to give the homologous aldehyde, the removal of 
the aldehyde group by Wolff-Kishner reaction and finally the Birch reduction of the 
anisole to give the compound XXV. The latter was then transformed into photoadduct 
XXVI, which was then converted into the mixture of ketols XXXa and XXXb which 
was separated chromatographically. The ketol endo XXXa was then converted into the 
benzoate exo XXXII by treatment of its tosylate XXXI with Et4N
+PhCOO-, taking 
average of the effect electron withdrawing of the adjacent carbonyl group to the 
bridgehead position which does not allow the rearrangement82. The 
bicyclo[2.2.2]eighty-2-ol XXXVb was then obtained in two ways: from the ketoester 
XXXII for deoxygenation followed by removal of the benzoate with LiAlH4 (Scheme 
10), or for methanolysis83 of the acetate XXVI (which was prepared from the ketol 
XXXa by inversion of configuration of the tosylate XXXI, followed by deoxygenation) 
(Scheme 11). The (+)-stemar-13-ene 40 was then obtained by treatment of the 
bicyclo[2.2.2]eighty-2-ol 30b with TsOH in benzene. 
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Scheme 10 : Trasformation of the ketol XXXa into (+)-stemar-13-ene 40 and into (+)-18-
deoxystemarin 50. 
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Scheme 11 : Trasformation of the intermediate XXXVI into (+)-stemar-13-ene 40 and into (+)-18-
deoxystemarin 50 
 
 
 
1.2.4. Stemarane diterpenes biological activity 
 
Stemarane diterpenes biological activity was not as deep evaluated as for other 
diterpenes, resulting in scarce literature references. An exception is found for the 
phytoalexin oryzalexin S 3917, whose antimicrobial activity was evaluated. As 
previously reported, the diterpenes were deeply studied in the past years especially in 
rice plants, with particular interest toward rice phytoalexins, not only from a biological 
activity point of view, but even for a better understanding of the phytoalexin mechanism 
of action, still unclear for most of the aspects. 
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1.2.5. Oryzalexin S 
 
Orizalessina S 39 is a tetracyclic diterpene (Figure 20). It was isolated from Rice plant, 
Oriza sativa L., in 1992 by Kodama et al. at Ibaraki University (Japan) and its 
molecular structure was established by the same research group. We don’t know the 
absolute configuration of the stereogenic centers but we know only the relative 
configuration, by means of a series of NMR experiments (13C-1H COSY, 1H-1H COSY, 
13C-1H HOHAHA, 13C-1H COLOC and NOESY)50. These experiments have allowed to 
establish the structural characteristics of this molecule: 
- has a stemarane diterpene skeleton where the bicyclic system C/D is costituited 
by a bicycle[3.2.1]octanic system; 
- there are seven stereogenic centers, five of which are contiguous [C (4), C (5), 
C (10), C (9) and C (8)], and two of which are adjacent quaternary carbons [C 
(9) and C (10)] 
Orizalessina S 39 was obtained from rice by UV irradiation. As known, this radiation 
stimulates the production of phytoalexins. After irradiation the rice was leaves in a 
incubation box with high humidity condition for 3 days. Then by chromatography the 
different phytoalexins formed were separated: from 200 g of rice leafs, 10.9 mg of 
orizalessina S 39 were obtained51. The fact that this molecule have interesting biological 
activity, which is obtainable in small quantities from the natural source and which has a 
skeleton complex, making it a valid target synthetic. 
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Figure 20: Oryzalexin S 
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An efficient Oryzalexin S synthesis, in fact, not only would be a success from the 
academic point of view, but also allow to study the structure-activity relationships. 
Now, Oryzalexin S synthesis in  literature are not reported, on the contrary have been 
developed several synthesis of other stemarane diterpenes.  
 
 
1.2.6. Rice phytoalexin biological activity 
 
Among the diterpene compounds, the most cited active ones are the kaurane 
derivatives for which, diverse biological activities have been described, including plant 
growth regulating, antimicrobial, antiparasitic, insect antifeedant, cytotoxic, antitumor, 
anti-HIV, steroidogenic, antifertility, hypotensive and antiinflammatory activities, 
described in the review published by Ghisalberti in 199752. Some of these kaurane 
biological effects have also been cited in recent literature53.  
Considering the biological activity of stemarane diterpenes, it was not as deeply 
studied as for the other diterpenes, thus resulting in a few literature citations. The most 
common and the most studied biological activity is the antimicrobial one, and in 
particular, the phytoalexin activity of oryzalexin S 39.  
Phytoalexins from rice mainly involve two types of diterpenes and flavones, including 
momilactones A and B, oryzalexins A-F, phytocassanes A-E, sakuranetin, and the 
stemarane diterpene oryzalexin S 3954 (Figure 21). The first phytoalexin with diterpene 
structure isolated were the momilattoni A and B in 198132a, followed by oryzalexin A-F 
and S29-32b,c,d-59a-64, and five phytocassanes32h-65.The momilattoni A and B and the 
orizalessine A-F were classified as pimarane diterpenes, the sakuranetin is a flavanoid, 
while the oryzalexin S belongs to the class of stemarane diterpenes. Momilactones A 
and B, among the plants belonging to the Gramineae family, were initially isolated as 
plant inhibitors from rice husk55, and were afterwards found to be produced in plant rice 
in response to either by the pathogen P. oryzae infection or by UV light irradiation56,32a. 
More recently, momilactones A and B have been found in rice root exudates, which 
participate in the defence against weeds57.  
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Sakuranetin was identified from rice plants infected by P. oryzae, and it showed high 
antifungal activity and a large amount of accumulation in rice leaves58. Oryzalexins A-F 
and S were isolated from rice leaves infected by P. oryzae59,17. Oryzalexins A-C 
strongly inhibited the spore germination of P. Oryzae: their ED50 values were 130, 68 
and 136 ppm, respectively. Complete inhibition of P. oryzae spore germination was 
observed at 200 ppm. Moreover, Oryzalexins A-C strongly suppressed the germ tube 
elongation of P. oryzae; indeed their ED50 values on P. oryzae germ tube elongation 
were 35, 18 and 35 ppm, respectively59a. 
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Figure 21: Common rice phytoalexins. 
 
In the same way, Oryzalexins D-F and S significantly inhibited spore germination of 
the rice blast fungus59b-c,17. Noteworthy, Oryzalexins E had slightly lower antifungal 
activity than Oryzalexins D, but higher than Oryzalexins A-C59c. In 1987 some chemists 
from the University of Ibaraki investigated the different activities of the enantiomers of 
Oryzalexins A-D, showing the higher antifungal activity of the (+)-enantiomers and 
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thus elucidating the great importance of the absolute configuration of these natural 
compounds60.  
Phytocassanes A-E are produced by the rice leaves and stems infected with the fungi 
P. oryzae and R. solani, exhibiting high activity against these pathogenic fungi as 
shown by the low value of ED50, reported in Figure 22
32h. 
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Figure 22: Structures of phytocassanes A-E and their antifungal activities (the ED50 values) on 
spore germination of P. oryzae. 
 
The relative small amounts of these substances released by the plant, the small 
knowledge of the mechanism of action of phytoalexins, and the disease resistance are 
the main difficulties in determining the antifungal activities of rice phytoalexins, and 
hence of the stemarane diterpene oryzalexin S 39. An increasing number of studies have 
shown that rice phytoalexins are induced by elicitors that are produced by pathogenic 
microorganisms and determine a field disease control by inducing the pathogen defence 
mechanism in rice61. Elicitors have been investigated extensively, and it has been 
demonstrated that jasmonic acid and its related compounds play an important role as 
signalling molecules eliciting the phytoalexins production in rice. Sakuranetin 
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production, for example, may be elicited by exogenously applied jasmonic acid in rice 
leaves, and its production by exogenously applied jasmonic acid was significantly 
counteracted by amino acids, cytokines, kinetin and zeatin61b-c. 
It has been shown in host-pathogen interactions that resistance reactions can be 
triggered by a large number of abiotic and biotic factors. Among the chemical factors, 
macromolecules of microbial origin are very important, stimulating plant defence 
responses at very low concentrations62. It was confirmed that some chemical substances 
may induce plant disease control by activating the natural resistance mechanisms of the 
host (for example, 2,2-dichloro-3,3-dimethyl cyclopropane carboxylic acid may exert its 
systemic fungicidal activity against the rice blast disease caused by P. Oryzae63). The 
application of methionine on wounded rice leaves induced the production of rice 
phytoalexins, sakuranetin and momilactone A. In the paddy field, methionine treatment 
has been demonstrated to reduce rice blast58. 
 
 
1.2.7. Photochemistry 
 
At the beginning of the twentieth century G. Ciamician, in an article published in the 
journal Science66, examined the problem of the development of photochemistry. After 
facing the question about the use of photochemical processes in plants (imagining a 
future in which the plants were grown in order to obtain their chemical compounds 
producted by photochemical processes), Ciamician wondered what would be the future 
development of photochemistry, which at that period was only at an early stage, and 
that could have been widen to different sectors in the years to come. 
He also realized that often the photochemical behaved in a manner not easily 
predictable, unlike the ordinary reactions of organic chemistry, but remained extremely 
confident of the benefits that this new technique would lead to chemists of the future. At 
a time when the industry exploited the coal, was the first to talk about green chemistry 
and the use of solar energy.  
On a very general photochemical processes involve two steps: 1. the production of an 
excited state and 2. events that determine the fate of the excited state. The absorption of 
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a quantum of radiation in the UV -VIS produces a high-energy species that dissipates its 
energy using mainly two fundamental processes of deactivation : 1. a chemical reaction 
that leads to a photoproduct and 2. a physical process that restores the ground state. 
Absorbing light, molecules reach an electronically excited state. As a result, the 
distribution of electrons in the molecules is significantly different at these states when 
compared to the ground state.  
In some cases, using photochemical steps significantly shortens a total synthesis, and 
frequently comple, polycyclic, or highly functionalized structures can be obtained from 
simple substrates. Photochemical substrate activation often occurs without additional 
reagents, which diminishes formation of byproducts. Due to this fact, photochemical 
reactions become particularly interesting in the context of green chemistry. Some of 
these reactions can be carried out with visible light or sunlight as a renewable energy 
source. Using light as a reagent also facilitates transformations inside supramolecular 
structures or crystals. Such fragile structures are not decomposed by aggressive reagents 
or heating. These transformations are often carried out in order to control the 
stereoselectivity of photochemical reactions; Irradiation with UV or visible light 
frequently improves the yields of metallocatalyzed reactions. For instance, ligand-
exchange steps are often accelerated, and irradiation with light has become part of the 
standard reaction conditions. Irradiation is also used to initiate radical chain processes 
under mild conditions. Thus, particularly complex radical reactions such as certain 
radical tandem or multicomponent transformations have become possible. 
 
 
1.2.7.1. [2+2]Photocycloaddition of α,β unsatured carbonyl 
compounds to alkenes: some examples on the total 
synthesis of certain natural compounds 
 
Among photochemical reactions, the [2+2] photocycloaddition of α,β-unsaturated 
ketones or esters to alkenes, alkynes, or allenes leading to cyclobutanes84 is certainly the 
most applied reaction in organic synthesis85-88. With α,β-unsaturated ketones, the 
reaction can be induced by simple light absorption. In many cases, the unsaturated 
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carbonyl compounds react at the 3pipi* state with alkenes and 1,4-biradical intermediates 
are generated. Their behavior significantly affects the outcome of the reactions86, 
particularly influencing the stereo- and regioselectivity. As shown in the examples 
reported below, through photocycloaddition reactions you can obtain complex 
structures in only one step without using and/or toxic reagent and this considerably 
simplifies the total synthesis of complex molecules such as natural products.  
The [2+2] photocycloaddition of various α,β-unsaturated lactones such as 50 (Figure 
23) has been studied in the context of an application to the total synthesis of 
Solanoeclepin A. As indicated by the arrows, only the crossed adduct was isolated. In 
one step, the tricyclic fragment containing a cyclobutane unit was obtained with the 
required relative configuration.  
 
O
O
C
50
hv
O
O
O
OMe
O
COOH
O
HO
O
OH
H
H
Solanoeclepin A
Solanoeclepin A
 
Figure 23 
 
In an analogous approach, the dioxyenone 51 (Figure 24) was transformed into 52 
via a [2+2] photocycloaddition. Compound 52 was then used as an intermediate in the 
first total synthesis of ingenol (Figure 24), a diterpenoid with unique architecture and 
has derivatives possessing important anticancer activity89. 
Another example of this reactions, reported in figure 24, is the first total synthesis of 
(+)-2β-hydroxysolanascone, the aglycone of the phytoalexin 2β-hydroxysolanascone-β-
glucopyranoside isolated from flue-cured tobacco leaves (N. tabacum L., OCL), which 
possess antibacterial activity90. 
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Figure 24 
 
A [2+2] photocycloaddition was also used, by Crimmins et al., as key step in the 
synthesis of Ginkgolide B 1 (Figure 25), a natural product which possess a propellane 
core structure, and photochemical reactions have frequently been applied for the 
synthesis of such derivatives91.  
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Figure 25: Crimmins’ key step in the synthesis of Ginkgolide B 1. 
 
 
INTRODUCTION AND OBJECTIVES 
 
36 
 
Under similar conditions, Mangion and MacMillan, reported the conversion in high 
yield of the cinnamic acid derivative 53 into (-)-Littoralisone via an interamolecular 
[2+2] photocycloaddition followed by hydrogenation (Figure 26). 
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Figure 26: Final step of a synthesis of (-)-Littoralisone 
 
Recently, Doroh and Sulikowski, studied the intramolecular [2+2] 
photocycloaddition of 5-alkylidene-2(5H)-furanone as a key step in the synthesis of 
Bielschowskysin (Figure 27), a diterpene possessing a [9.3.0.0] tetradecane ring system 
with 11 stereocenters. 
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Figure 27: Key step in the synthesis of Bielschowskysin 
 
De Mayo reaction is a versatile variant, in synthetic application, of the [2+2] 
photocycloaddition. A recent example of this reaction is reported in figure 28: 
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Figure 28: Synthetic application example of De Maio reaction 
 
In its enol form In its enol form, a β-diketone reacts as an α,β-unsaturated ketone 
with an alkene. This step is followed by a retro-aldol reaction. In compound 54, the 
mono-enolized β-diketone chromophore adds to the enamine part of the isoquinolone 
moiety and the tetracyclic aldol 55 is obtained as an intermediate92. Due to ring strain, 
the latter is immediately transformed into 57. After an intramolecular aldol reaction, the 
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more stable tetracyclic hydroxyketone 56 is isolated. Compound 56 possess the 
galathane skeleton which is encountered in Lycorine alkaloids isolated from 
Amaryllidaceae
93. 
As reported in figure 29, a range of naturally occurring cyclobutanes have been 
synthesized by using intramolecular [2+2] photocycloaddition. One such example is 
(+)-Solanascone 58, the biosynthesis of which [from (-)-Solavetivone]is through to 
occur photochemically. Further examples include (±)-Italicene 59, (±)-Isoitalicene 60, (-
)-Elecanacin 61, (±)-Trihydroxydecipiadiene and (+)-Dehydrosolanascone. 
 
O
58
R1
H
R2
59 R1 = Me; R2 = H
60 R1 = H; R2 = Me
O
O O
O
H
61
 
 
Figure 29: The naturally occurring cyclobutanes (+)-Solanascone 58, (±)-Italicene 59, Isoitalicene 
60, (-)-Elecanacin 61, which where synthesized by intramolecular [2+2] photo-
cycloadditions. 
 
As previously mentioned, photochemical reactions have frequently been performed 
in supramolecular structures since the reaction conditions are particularly mild. In the 
case of an intramolecular [2+2] photocycloaddition, stereoselectivity can be induced 
inside such a host/guest structure. For example, the quinolone derivative 62 was 
complexed with the template structure 64 (Figure 30)94. Photocycloaddition yielded the 
cyclobutane derivative 63 with high enantioselectivity. Numerous intra- and 
intermolecular photochemical reactions have been performed under analogous 
conditions using host structures such as 6495-96. 
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Figure 30 
 
Intermolecular [2 + 2] photocycloadditions have also been studied and represent a 
facile and versatile access to cyclobutane derivatives. For example, the enantiomerically 
pure uracil derivative 65 reacted via a sensitized [2+2] photocycloaddition with ethylene 
to yield the corresponding cyclobutanes 66a and 66b (Figure 31)97. The 
diastereoselectivity of this reaction was low98, but the stereoisomers were easily 
separated and then transformed into the β-amino acids 67 and ent-67.  
Similar products resulting from intra- or intermolecular [2+2] photocycloaddition 
have frequently been applied to the synthesis of β-amino acids99-100. When incorporated 
in a peptide structure, such β -amino acids have a significant influence on the secondary 
and tertiary structure of these compounds. In particular, 2-aminocyclobutane-1-
carboxylic acid moieties rigidify a peptide structure in such a way that a helix secondary 
structure is induced101.  
In this context, the acyclic β-amino acid of a Rhodopeptin derivative was replaced by 
a cyclobutane analog, prepared via [2+2] photocycloaddition of ethylene to a 
corresponding uracil derivative102. Rhodopeptins are cyclic lipopeptides isolated from 
Rhodococcus sp. Mer-N1033 possessing antifungal activities. 
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Another important class of photochemical reactions frequently used in organic 
synthesis use copper as catalyst: two examples are reported in figure 32. 
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Figure 32 
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(±)-Kelsoene was synthesized from the diene 68 (Figure 32)103. This sesquiterpene was 
also obtained using the corresponding addition of ethylene to an α,β-unsaturated 
ketone104. The copper-catalyzed [2 + 2] photocycloaddition is very versatile and has 
often been applied to asymmetric synthesis. For instance, (-)-grandisol, a component of 
the aggregation pheromone of the male boll weevil (Anthonomus grandis) was obtained 
from compound 69 with a copper-catalyzed [2 + 2] photocycloaddition as the key step 
of the synthesis (Figure 32)105. 
 
 
1.3. Stemodane diterpenes 
 
As previously reported, the Stemodia Maritima is a plant belonging to the family 
Scrophulariaceae and it is found in tropical and subtropical regions of the world9.  
In fact, this plant, grows widely in the Virgin Islands and the region to the North-East of 
Brazil, near the sea, where it is known as "Melosa"106 . This plant is known for a long 
time in traditional medicine of the population in the north of South America and in most 
of the Caribbean islands, and is used for the treatment of venereal diseases 10a. 
Although Stemodia includes about 40 species, the chemical investigation of this kind 
is limited to 5 species (S. maritima, S. chilensis, S. kingii, S. viscose, S. foliosa)107 from 
which were isolated flavonoids, labdane diterpenes and some tetracyclic diterpenes with 
a rare skeleton called stemodane skeleton (Figure 33). 
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Figure 33: stemodane skeleton  
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Diterpenes with the stemodane skeleton, isolated from Stemodia Maritima, are 
stemodin 7011a, stemodinone 7111a, 2-deoxystemodinone 7211a and maritimol 7310a 
(Figure 34). From the same plant was also isolated stemarin 338, the founder of the 
stemarane diterpenes. As point out before, the structure of stemarin 33 has been 
established by X-ray diffraction. 
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73    R1 = R2 = H, R3 = OH
33
 
 
Figure 34: stemodin 70, stemodinone 71, 2-deoxystemodinone 72, maritimol 73 and stemarin 33. 
 
In 1990 in Chile, Garbarino and co-workers described the isolation, from Chilean 
Calceolaria Lepida, of a new diterpenoid. Garbarino and co-workers had originally 
speculated that the diterpenes of Calceolaria could have a stemodane or stemarane 
skeleton, opting, then for the latter. 
The structure of this new diterpenoid 15, (-)-2-deoxyoryzalexin S, was attribuited, by 
Garbarino, on the basis of the 1H and 13C NMR spectra,. To this compound, as well as 
to its congeners, the absolute ent-stemarane configuration was assigned on biogenetic 
grounds. 
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1.3.1. Structure of stemodane diterpenes 
 
The stemodane diterpenes carbon skeleton is reported in figure 35, and its main 
structural characteristics are reported below: 
• the bicyclic system C/D is constituted by a bicyclo[3.2.1]octane fused to the 
bicyclic A/B system; 
• there is a quaternary carbon spirocyclic, the C (9), adjacent to a second 
quaternary carbon, the C (10); 
• oxygenated functions can be present at C(2), C(3), and C(13).  
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Figure 35: Stemodane diterpenes carbon skeleton 
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1.4. Kaurane diterpenes 
 
Kaurane diterpenoids, whose parent compound is the kaurane (Figure 36), are an 
important class of natural product known from the beginning of this century and 
widespread in the plant kingdom.  
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Figure 36: kaurane (73), ent-kaurene(74) and kaurenoic acid (75) 
 
Kaurene 73 (Figure 36) was first isolated by Hosting from the leaf oil of Kauri pine, 
a resinous conifer native of the island north of New Zealand and belonging to the family 
of Agathis australis. Later it has been obtained from Podocarpus macrophyllus as well.  
The structures of kaurane diterpenes are well-known: they contain a rigid tetracyclic 
scheleton costituited by a perhydrophenantrene unit (A, B and C rings) fused with a 
cyclopentane unit (D ring) formed by a bridge of two carbons between C-8 and C-13 
(Figure 37)108. 
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Figure 37: Carbon-skeleton of an ent-kaurane diterpene 
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Kaurane diterpenoids, and in particular kaurenoic acid 75 (Figure 36), are important 
intermediates in the biosynthesis of a number of plant and fungal metabolites, including 
Gibberellin, a well-known class of phytohormones involved in the regulation of plant 
growth. 
 
 
Figure 38 
 
Several biological activities of kaurane diterpenes have been described in literature 
such as, antimicrobial109, antiparasitic109, antiinflamatory109, hypotensive109, insect 
antifeedant109, antifertility109, cytotoxic109, antitumour109, anti-HIV109 and plant growth 
regulation110. 
Some of these kaurane biological effects have also been cited in the review published 
by Ghisalberti in 199752a. 
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1.4.1. Some examples of Kaurane diterpenes in Nature 
 
 
In 1964, Henrick and Jefferies111, from the ethereal extract of Ricinocarpus stylosus 
belonging to Euphorbiaceae family, obtained four new kaurenoid diterpenes: 19-
hydroxy-16α-(-)-kauran-17-oic acid 79, (-)-kaur-16-en-19-oic acid 78 and 16α-(-)-
kauran-l7,19-dioic acid 76, kauran-16α,-17,19-triol 77 (Figure 39).  
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Figure 39: New kaurene derivatives by Henrick and Jefferies in 1964. 
 
 
Moreover, starting from compound 76, Henrick & Jefferies111 obtained other 
derivatives, by the common chemical reactions. 
In 1968, Mori et al.112, carried out the total synthesis of kaurenoic acid 75 . Four 
years later, in 1972, the same group accomplished the synthesis of the Gibberellins A2 
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(80)113, A4 (81)
113, A9 (82)
113 and A10 (83)
 113 and Steviol (84)114(Figure 40). In these 
papers they describes the synthesis of suitable kaurane derivatives which are 
functionalized on the ring A.  
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Figure 40. 
 
 
In 1988, Bellino and Venturella115, reported the synthesis of ent-7β,17,18-
trihydroxykaur-15-ene 85 (sinfernol), ent-15β,16β-epoxy-7β- trihydroxykaurane 86 
(epoxysinfernol) and ent-7β,15β-trihydroxykaur-16-ene 87 (canditriol) the constituents 
present in the aerial part of Sideritis infernalis a species endemic to the Canary Island, 
using as starting material an abundant diterpene of Sideritis infernali,s ent-7β,18β-
dihydroxykaur-15-ene 88 (episideridiol) (Figure 41). 
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Figure 41. 
 
 
In 1987, the Corey group116a achieved the total synthesis of (±)-atractyligenin 89. 
Ten years later116b, however, they reported a novel catalytic enantioselective synthetic 
route to the preparation of 89 with an enantiomeric excess over 87 % (Figure 43).  
 
In 2004 Britton, Piers and Patrick reported the total synthesis of (±)-13-methoxy-15-
oxozoapatlin 90 (Figure 42), an interesting diterpenoid which was found to be active as 
a cancer therapeutic agent and it has shown antimalarial activity. This synthesis consists 
of 21 steps and it is a new method for the construction of the functionalized 
bicyclo[3.2.1]octane unit. 
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Figure 42. 
 
In 2002, Vieira et coll.117 reported the synthesis of 12 new derivatives of kaurenoic 
acid 75 with the aim either to improve the therapeutic activity against trypomastigote 
forms of Trypanosoma cruzi, either to reduce the lytic activity of the kaurenoic acid 75 
on blood erythrocytes. Among the derivatives prepared, compound 92 (Figure 43)  
showed more enhanced trypanosomicidal activity in vitro than kaurenoic acid 75 but it 
kept discrete lytic activity on erythrocytes. 
Moreover, they found that compound 91 (Figure 43) did not show lytic activity but 
has similar level of activity as kaurenoic acid 75. All the other derivatives of kaurenoic 
acid 75 were completely inactive against Trypomastigote forms of Trypanosoma cruzi 
at the concentrations tested (2.27 – 0.57 mM). 
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Figure 43: Two of the some derivatives synthesized by Vieira et coll., in 2002 
 
 
INTRODUCTION AND OBJECTIVES 
 
50 
 
The well-known biological activities of kaurenoic acid 75 and the relatively high 
natural abundance of this diterpene, stimulated Boeck et coll.118, to synthetize kauranoic 
acid 78 and derivatives in order to evaluate their potential pharmacological activities. 
Boeck et coll., in 2005, tested all their synthetized compounds for antifungal activity 
against human opportunistic pathogenic fungi including  yeast (such as Candida 
albicans, C. tropicalis, Saccharomyces cerevisiae and Cryptococcus neoformans, the 
filamentous fungi Aspergillus niger, A. flavus and A. fumigates, etc.), 
hialohyphomycetes and dermatophytes (Microsporum canis, M. gypseum, Trichophyton 
rubrum, T. mentagrophytes and Epidermophyton flocco sum). They observed that only 
kaurenoic acid 75 and derivatives containing the acidic -COOH group displayed a 
moderate activity against three dermatophytes (Trichophyton rubrum, T. 
mentagrophytes and Epidermophyton flocco sum), indicating that the presence of 
hydrophilic groups contributes to the antifungal activity. 
 
75 R = H
93 R = CH3
94 R = CH3CH2CH2CH2
95  R =PhCH2
96 R = 4-ClPhCH2
97 R = 4-BrPhCH2
H
H
CO2R
H
H
CONHR
98   R = Ph
99   R = PhCH2CH2
100 R = PhCH2CH2CH2CH2
H
H
CO2R
101 R = H
102 R = CH3  
Figure 44: Kaurenoic acid (75) and some derivatives (93-102) synthetized by Boeck et coll. 
 
 
INTRODUCTION AND OBJECTIVES 
51 
 
 
In 2005, Alonso et coll.119, starting from (-)-kaur-9(11),16-dien-19-oate, which was 
isolated from Venezuelan species of Espeletia (Asteraceae), have synthetized the 
diterpenes 103 and 104 (Figure 45) evaluating their antimicrobial and antitumoral 
activity. The results obtained, showed that these compounds have high cytotixic and 
cytostatic activity against diverse neoplastic cancer cell lines (such as colon, lung, 
leukemia, melanoma, ovary, kidney and prostate). 
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Figure 45: diterpenes prepared by Alonso et coll. 
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1.4.2. Previous synthesis of Kaurane diterpenes  
 
Many synthesis of kaurane diterpenes are reported in the literature and a review on 
this topic was published by Goldsmith. Common aspect of some synthesis reported by 
Ireland on Kaurene 105, by Mori on Kaurenoic acid 75 and by Fujita on kaurendiol 106, 
concerns the formation of the D ring of the kaurane system by cyclization of a 
phenanthrenic substituted system as shown in figure 46: 
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Figure 46: D ring of the kaurane system by cyclization of a phenanthrenic substituted system. 
 
In the synthesis of Ireland and co-workers (Scheme 12), there is a protection of the 
aldehyde function IV with the formation of the acetal group V. The latter was then 
subjected to hydroboration and oxidation and converted into ketones VI and VII in ratio 
1.6:1. 
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Scheme 12: Synthesis of Kaurene (105) by Ireland 
 
The carbonyl function at C(14) allows, after acid treatment of the ketoacetalic 
system, the rearrangement to the kaurenoic skeleton through intramolecular aldol 
condensation. Then, the resulting compound III is converted into kaurene through two 
independent reaction pathways, as reported in the scheme 12 in one-way of these 
patways, the hydroxyl group is protected and the carbonyl group is removed by Wolff 
Kishner reduction. Then the hydrolysis of the protected group restores the carbonyl 
function and through a reaction of Wittig you will come to the formation of kaurene. the 
other way of these patways, concerns the selective methylation the dione VIII, which 
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was previously obtained by treating compound III with CrO3, using a phosphorus ylide 
to give IX. The subsequent deoxygenation of IX leads to the formation of kaurene 105. 
The defect of this synthesis is given by the fact that the ketone VI is obtained in a not 
regioselective way. 
Mori and co-workers, for the synthesis of the kaurenoic acid 75, follows the general 
approach used by Ireland for the kaurene synthesis (Scheme 13).  
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Scheme 13: Synthesis of the kaurenoic acid (Ic). a)NaOCH3; b)1.KO-t-Bu/MeI, 2.(HSCH2)2/BF3, 
3.Ra-Ni; c)1. Rh-Pt/H2, 2. CrO3; d)1. HCO2Et/NaOCH3, 2.n-BuSH/TsOH, 3. KO-t-Bu/ 
CH2=CHCH2Br, 4.KOH; e)1.OsO4,HIO4, 2.NaOCH3, 3.DHP/p-TsOH, 4.N2H4/KOH; f) 
1.H3O
+
, 2.CrO3; g)1.CH2N2, 2.(HOCH2)2/TsOH, 3.LiAlH4, 4.HCl, 5.Ph3=CH2; h) CrO3 
 
The tricyclic compound XI was prepared by Robinson annulation of the β-tetralone 
X. Then, the alkylation followed by the reduction of the double bond and the ketone 
group led to the formation of the ester XII. The reduction of the aromatic ring, followed 
then by Jones oxidation, led to the tricyclic ketone XIII. The C/D rings system was then 
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builted using the approach by Ireland through the allylation of a protected ketone, the 
cleavage of the allylic unit, to give a keto-aldehyde, intramolecular aldol condensation 
and Wolff Kishner reduction. In this way the ketone XIV was obtained. The latter was 
then converted into kaurenol XV which was later transformed into kaurenoic acid 75. 
In the synthesis of the kaurene-11,15-diol 106, by Fujita and Ochiai (Scheme 14), the 
key step is the regioselective formation of the unsaturated β,γ-ketone XVI. 
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Scheme 14: Principal steps of the kaurendiol’s synthesis (156) by Fujita and Ochiai 
 
The compound XVI was prepared by Fujita and Ochiai by several synthetic steps 
(such as Robinson annulations, methylations, desulphurization and Birch reduction) 
using 5-metoxy-β-tetralone XVIII as starting material. Then by epoxidation and  by 
elimination base-catalyzed, the hydroxyl-enone XIX was obtained. The two carbon 
atom unit, required for the five terms D ring, is formed selectively by using the 
hydroxyl group at C(11) of the compound XIX as orienting group. The latter was 
converted into compound XX by Claisen rearrangement. 
The product of the Claisen rearrangement XX, through several steps (aldol 
condensations, Collin’s oxidation, Wolff-Kishner reduction, hydroboration, Jones’ 
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oxidation, isomerization and photosensitized oxygenation), is then transformed into the 
natural product kaurendiol 106. 
A synthesis of kaurene 107 was also conducted by Masamune and co-workers 
(Scheme 15). Unlike other researchers, they have built before the system of rings B/C 
and subsequently, by intramolecular cyclization, obtained the D ring. Then by Robinson 
annulation, A ring was built. 
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Scheme 15: Synthesis of the kaurene by Masamune. A)1. (COCl)2, 2.CH2N2, 3. HBr; B)1.NaBH4, 
2.DHP/H
+
, 3.Pd(C)/H2; C)1.KOt-Bu, 2.H3O
+
, 3.PhCOCl; D)1.Pd(CaCO3)/H2, 
2.Ph3CNa/CO2, 3.CH2N2; E)1.Pent-1-en-3-one/OH
-
, 2.DHP/H
+
; F)1.KOt-Bu, 2.H3O
+
, 
3.CrO3; G)1.H2/Pd, 2.(HOCH2)2/H
+
, 3.N2H4/KOH; H)1.LAH, 2.CrO3/pyr., 3. 
N2H4/KOH. 
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1.4.3. Some examples of Kaurane glycosides 
 
In chemistry, “Glycoside” is a molecule in which a sugar is bound to another functional 
group via a glycosidic bond. Glycosides are widely distributed innature and they play 
numerous important roles in living organisms. Many plants store chemicals in the form 
of inactive glycosides. These can be activated by enzyme hydrolysis120, which causes 
the sugar part to be broken off, making the chemical available for use. Many such plant 
glycosides are used as medications. In animals and humans, poisons are often bound to 
sugar molecules as part of their elimination from the body. 
In the last 40 years, kaurane glycosides have assumed a great importance because of 
their toxicity, potential therapeutic and economic value have been demonstrated.  
Some of the most important examples of these class are stevioside 110, atractyloside 
108, carboxyatractyloside 109 and wedeloside 111, the structures of which are shown in 
figure 47. 
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Stevia rebaudiana Bertoni (Asteraceae family)(Figure 48), is a native plant of 
Paraguay and Brazil; infact its leaves have been traditionally used for hundreds of years 
by natives of Paraguay and Brazil as a “sweet treat” and also for its medicinal benefits. 
Later it has been cultivated also in Israel, South and North Korea, China and Japan. 
 
 
Figure 48: Stevia rebaudiana Bertoni leale 
 
The first news of the existence of this plant came from its use by the indigenous 
Guarani which called Caa-eh-è (sweet grass) or sweet chrysanthemum and used it to 
cover the bitter taste of the “Ilex paraguayensis” by which they prepared a brew called 
"Mate "(Paraguayan tea) slightly stimulant for its low caffeine content.  
Stevia rebaudiana was described for the first time by Moises Santiago Bertoni 
(1857-1929), a Paraguayan botanist, such as Eupatorium rebaudianum. Then it was 
classified in the genus Stevia, by William Botting Hemsley (1843-1924), a British 
researcher of the Kew’s Botanical Gardens. The name "rebaudiana" it has been given to 
this plant in honor of the chemist Rebaudi who first studied the chemical characteristics 
of the substances contained in the plant. 
More than 150 species of Stevia have been described, but rebaudiana it is the only 
one possessing sweetening properties. Its leaves contain a complex set of diterpene 
glycosides. These substances are characterized by the presence in their structure of three 
molecules of glucose. About the four sweeteners (Stevioside, Rebaudioside A, 
Rebaudioside C and Dulcoside A), present in higher concentrations in the leaves, 
stevioside 110 (3-10% of the dry weight of the leaves) and rebaudioside A (1-3%) have 
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physical and sensorial properties well characterized with a sweetness of 110-270 and 
180-400 times higher than sucrose, respectively. In fact for these properties and for the 
reason that do not show any carcinogenic activity, the industrial use of the stevioside 
110 as a substitute for saccharose, in foods and dietary drinks is allowed in some 
countries around the world. In medicine it is used as an anti-hyperglycemic agent for the 
treatment of diseases of the skin, in the treatment of hypertension for its cardiotonic 
action and for many other diseases. 
The study of some species of Stevia spp. has led to the isolation of several other 
kaurane glycosides, with or without sweetening properties121. 
 
Atractyloside 108 (Figure 47), initially isolated from rhizomes of Atractylis 
gummifera L. (Asteraceae)122, and then from Wedelia glauca Ort. (Asteraceae)123, it is 
also present in a number of plants used as ethnomedicines throughout Africa, the 
Mediterranean areas and the Far Eastern countries. 
 
  
Figure 49: (left) Wedelia glauca Ort. and (right) Atractylis gummifera L. 
 
Atractyloside 108 is a natural compound that functions as a specific inhibitor of the 
adenine nucleotide translocase (ANT), a mitochondrial ADP/ATP carrier. Additionally, 
Atractyloside is a proapoptotic ligand of ANT that induces pore formation by ANT, and 
results in the permeabilization of the mitochondria membrane. In fact it is the main 
compound responsible for the lethality of these plants in bovine cattle of some regions 
of Argentina, Brazil and Uruguay. Its toxic action is due to the inhibition of 
mitochondrial oxidative phosphorylation122, causing hypoglycemia, respiratory 
depression, nephrotoxicity, hypoxemia and cell injury.  
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In 2001, Obatomi, Blackburn, and Bach124 dimostrated that in humans these 
compounds can cause renal and hepatic failure, also followed by necrosis.  
This toxic action is due to the inhibition of mitochondrial oxidative 
phosphorylation122.  
 
In 2005, Konopleva et coll.125, from the aerial parts of Gnaphalium sylvaticum 
(Asteraceae family) isolated a new diterpene glucoside, named Sylviside 112 (Figure 
50). 
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Figure 50: Sylviside 
 
 
The structure of compound 112 was elucidated by spectroscophic analysis (1H-NMR, 
13C-NMR, HMQC, HMBC, NOESY) and by X-ray crystallographic analysis. Sylviside 
112 displayed cytotoxic activity against HeLa WT cells, human epitheloid cervical 
carcinoma. 
 
Carboxyatractyloside 109 (Figure 47), have been isolated from Atractylis gummifera 
L., Xanthium spp. (Asteraceae), Wedelia biflora (Asteraceae), Cestum paraqui 
(Solanaceae) and Iphiona aucheri (Asteraceae)126,127,128 and it is also contained in the 
seeds of Xanthium strumarium (Cocklebur), an herbaceous annual plant found in the 
U.S. along the shores of streams and ponds and in low-lying areas of farm fields. 
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Figure 51: Xanthium strumarium 
 
This plant is highly toxic to animals. It inhibits of the nucleotide translation through 
the mitochondrial membrane, causing 10 times more toxicity than atractyloside 108. In 
fact Turgut et coll134, reported that this glycoside is a highly selective and potent 
inhibitor of the Adenine nucleotide translocator (ANT), the nucleoside binding site of 
ANT on the cytoplasmic side of the inner membrane and blocks the exchange of matrix 
ATP and cytoplasmic ADP. 
Carboxyatractyloside 109 showed, among other activities, antitumoral action against 
melanoma cells and Erlich tumour129, beyond the insecticidal and herbicidal 
activities130. 
 
In 1981 Mac Leod, Lewis and Moeller131 elucidated the structure of the diterpene 
aminoglycoside Wedeloside 111 (Figure 47), the major toxic constituent of the plant 
Wedelia asperrima Benth. (Asteraceae). Biochemical studies have shown that 
compound 111 is a powerful inhibitor of mitochondrial ADP/ATP transport, with a 
binding affinity to the carrier protein comparable to that of the related diterpene 
glycoside carboxyatractyloside 109. 
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Figure 52: Wedelia asperrima Benth. 
 
In 1990, Herigaya et coll.132, reported the isolation of three ent-kauranoid 
diterpenoids 113, 114 and 115 (Figure 53), from the acqueous extract of the aerial part 
of Artemisia sacrorum Ledeb. This plant distribuited in the Northeast District of China, 
is known as a Chinese folk medicine in the treatment of hepatitis. 
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Figure 53 
 
Herigaya et coll.132, moreover,elucidated the structure of these three compounds by 
means of NMR analysis (DEPT, 1H-1H COSY, 1H-13C COSY and 1H-1H decoupling). 
 
INTRODUCTION AND OBJECTIVES 
63 
 
In 1996, Zhau et coll.133, reported the isolation of two diterpene glycosides 116 and 
117(Figure 54) obtained from the flowers of Inula britannica L. (var. chinensis) 
(Asteraceae), used for the treatment of bronchitis and inflammation in the Chinese 
traditional medicine. 
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Figure 54: Two diterpene glycosides isolated by Zhau et coll. in 1996. 
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1.4. Objectives of this Ph.D. thesis 
 
The first objective of this thesis was that of evaluating a methodology recently 
disclosed in our laboratory for the construction of stemarane diterpenoids. The first 
target was (+)-2-deoxyorizalexin S. Its obtaining would have also allowed to confirm 
the structure and absolute configuration of a Chilean Calceolaria diterpenoid to which 
the structure of (-)-2-deoxyorizalexin S had been attributed in the past. The original 
isolated material is, in fact, no longer available for direct comparison. The obtaining of 
(+)-2-deoxyorizalexin S would have also allowed to use this material to verify the role 
of HO-C(2) for phytoalexin activity. 
The second objective derives from the first one. In fact obtaining of (+)-2-
deoxyorizalexin S allowed also to demonstrate the incorrectness of the structure 
attributed to the diterpenoid isolated from the Chilean Calceolaria. 
Searching for the structure of this unknown compound stemod-(13)-en-(19)-ol was 
therefore prepared from an intermediate of the previous synthesis. Also in this case no 
matching with the diterpenoid isolated from the Chilean Calceolaria was observed. 
On conclusion of this section of the thesis the third objective was taken-up, that is a 
new approach to the synthesis of kaurane diterpenes whose importance was highlighted 
above.  
This work has not been yet concluded. 
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Results and discussion 
 
2.1 Retrosynthetic analysis for (+)-2-deoxyoryzalexin S 
 
For the obtaining of the target (+)-2-deoxyoryzalexin S 1, (+)-podocarpic acid, from 
which chiron enone 5 was derived, was chosen as starting material and thus as chiral 
template (Scheme 16). 
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Scheme 16: Retrosynthetic approach to (+)-2-deoxyoryzalexin S 1. 
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A synthetic strategy that provides a serviceable approach to stereochemically 
complex structures can take advantage of the existence of the chiral pool, that is the set 
of natural compounds in which stereogenic centers are present in a defined 
configuration. Through a careful examination of the literature, Hanessian has collected 
several examples where a natural product is transformed into a chiral synthon, which he 
calls chiron. The chiron contain one or more stereogenic centers of the template. 
At the beginning of his studies on the design of a synthesis, Corey had introduced the 
term synthon1,2, an ideal fragment that you get through the process of disconnection of a 
bond. As previously mentioned, his innovative idea was then taken up and revised by 
Hanessian who brought the new concept of chiron. The term chiron means a "molecule 
or an enantiomerically pure intermediate that contains a high functional overlap and 
stereochemistry with a substructure of the target molecule"3. To use this strategy it is 
necessary, first, the examination of the molecular structure of the target, in order to 
recognize the configuration and position of the stereogenic centers present. They must 
then be placed in relation with those of the carbon backbone of chiron, which, in turn, is 
derived from the chiral template.  
The combination of natural chirality, conformational constraints and topological 
constraints in carbohydrates leads to locate between their structures a skeleton 
carbonaceous able to ensure a high regio- and stereochemical control. The next step 
consists in the search for a good overlap between the stereogenic centers and the 
functions of the template with those of chiron chosen for the preparation of a 
stereochemically complex compound. Sometimes the chiron may present a considerable 
degree of functional overlap and stereochemistry with target, and in part preserves its 
starting structure which constitutes the template. In other cases, however, it may be 
difficult to recognize inside the chiron the structure of the final compound, as happens 
when the stereocenters must undergo inversion or the rings must undergo cleavage. 
Thus, if a chiral product must be obtained from a carbohydrate, it is first necessary to 
compare the functional groups and the absolute configuration of the stereogenic centers 
of the desired product and the monosaccharide in question. This approach is valid if 
there is a similarity between the structure of the natural compound and that present in 
the target (or part of it). 
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If one wants to plan the synthesis of an organic compound it necessary to apply to 
retrosynthetic analysis4-6 which consists in reconstruct backward stages of molecular 
construction that will constitute the synthesis process. 
It is a technique to solve the problem of synthesis developed by E.J. Corey, described 
by him in 1990 in the Nobel Prize Lecture, based on the transformation of the molecule 
to be synthesized (synthetic target = synthetic TarGeT = TGT)7 in easier structures until 
a commercially available precursor, is identified. 
To the target structure is accompanied the application of a transform, the exact 
opposite of a synthetic step, and each structure identified by retro-analysis becomes, in 
turn, target for a subsequent retro-analytic operation. The repetition of the retro-analytic 
stages produces a tree of intermediate (EXTGT) with different hypothetical synthetical 
ways to obtain the target molecule. To each transform is related a retron, the structural 
unit key present in the target, which allows the application of the particular transform. 
 
 
2.1.1 From (+)-podocarpic acid 20 to the intermediate 3, a 
precursor of chiron 5. 
 
In the first step of the synthesis, both the carboxyl group at C(19) of (+)-podocarpic 
acid 20 and the phenolic function were methylated. The methylation reaction was 
conducted under basic conditions with dimethyl sulphate. The formation of the 
dimethylated product 2 was confirmed by the presence in the 1H-NMR spectrum of a 
singlet at 3.77 ppm, relative to the aromatic methoxyl and of another singlet at 3.66 
ppm, relative to the methyl ester group.  
The 13C-NMR spectrum showed a signal at 178 ppm relative to the carbonyl ester 
function and a signal at 55.4 ppm relative to the methoxyl carbon. The IR spectrum 
showed a band at 1719 cm-1 attributable to an ester carbonyl. Finally, as a further 
confirmation, GC-MS analysis gave a  molecular peak at m/z = 302. 
The ester group of compound 2 was then reduced with LiAlH4, to give the alcohol 3 
(Figure 55). The reduction reaction was carried out in anhydrous THF and the presence 
of the alcohol group was confirmed by the 1H-NMR spectrum in which it appears an 
AB system, consisting of two doublets at 3.88 ppm and 3.52 ppm, attributable to the 
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protons of the group -CH2-OH, and a multiplet at 2.31 ppm to 2.26 ppm relative to the 
proton of the hydroxy group. Moreover, we noted the disappearance of the singlet at 
3.66 ppm relative to the three protons of the methyl ester function. 
 The 13C-NMR spectrum showed a signal at 65.2 ppm, characteristic of a carbon 
directly bonded to an oxygen, and the disappearance of the signal at 178 ppm  
associated to the ester carbonyl. In the IR spectrum it was possible to note the 
disappearance of the band at 1719 cm-1 of the ester function. Finally, GC-MS analysis 
gave a molecular peak at m/z = 274. 
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Figure 55: Synthesis of intermediate 3 
 
 
2.1.2 Synthesis of chiron 5 
 
Before reducing the aromatic ring by the Birch methodology, it was necessary to 
protect the alcohol group. TBDMSilyl ether was chosen as the protecting group for its 
stability under the conditions of the Birch reaction. Thus compound 3 was reacted with 
TBDMSiCl and imidazole in anhydrous THF (Figure 56). 
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Figure 56: Synthesis of intermediate 4 
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The formation of the compound 4 was confirmed by the presence in the 1H-NMR 
spectrum of a singlet at 0.92 ppm relative to the nine protons of the t-butyl group and a 
doublet at 0.05 ppm attributable to the two methyls bound to silicon. The 13C-NMR 
spectrum showed two signals around -5 ppm attributable to the two methyls bound to 
the silicon and a very intense signal at 25.9 ppm relative to the methyl of the t-butyl 
group. As a further confirmation GC-MS analysis, gave the peak of the molecular ion at 
m/z = 388.Compound 4 was then subjected to Birch reduction with lithium in liquid 
ammonia and t-BuOH to give a dienolether, which was then hydrolyzed in  acid 
conditions to give the chiron 6 (Figure 57). During this step the removal of the 
protecting group of the HO-C (19) also occurred. 
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Figure 57: Synthesis of chiron 5 
 
The 1H-NMR spectrum confirmed the obtaining of the compound 5 through the 
disappearance of the signals at 6.98-6.66 ppm, a multiplet related to the three protons of 
the aromatic ring, and the singlet of the three protons of the methoxyl group at 3.79 
ppm. The 1H-NMR spectrum showed a singlet at 5.86 ppm attributable to the olefinic 
proton C(11). The IR spectrum showed the band relative to the stretching of conjugate 
C=O at 1661 cm-1. Moreover the GC-MS analysis gave the peak of the molecular ion at 
m/z = 262. In this step (conducted under conditions which would permit equilibration at 
C(8)-vinylogous), compound 5 was obtained as a single product because the epimer that 
have the  HC(8) β-oriented is the more stable. 
Through photochemical addition of allene to compound 5 (Figure 58), a four-cycle 
term was built. The reaction was carried out in anhydrous THF, at -78 ° C after having 
condensed the gaseous allene inside the solution. The latter was then irradiated at -78 ° 
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C through Pyrex with a Hg vapor lamp, which allowed the transition of type n-pi* of the 
non-bonding electrons of the oxygen of the carbonyl. The formation of the photoadduct 
(+)-6 was confirmed by NOESY experiments which showed a cross-peak between the 
HC(11) and CH3-C(10), that allowing us to establish the stereochemistry of the newly 
formed cyclobutane ring.  
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Figure 58: Synthesis of photoadduct 6 
 
The regiochemistry of the photoaddition followed from the dowfield shift (about 1.5 
ppm) of HC(11), adjacent to both a double bond and a carbonyl function, compared to 
that of H2C(13). The IR spectrum showed the band relative to the stretching of 
conjugate C=O at 1686 cm-1. 
 
 
2.1.3 Synthesis of compound 8 
 
Prior to methylation at C(13), it was necessary to protect as the tert-
butyldimethylsilyl ether the HO-C(19) of photoadduct (+)-6. The compound 6 was, 
therefore, reacted with TBDMSiCl and imidazole in anhydrous THF (Figure 59). 
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Figure 59: Synthesis of intermediate 8 
 
The formation of the intermediate 7 was verified by the 1H-NMR spectrum in which 
it appears a singlet at 0.06 ppm relative to the six protons of the methyl groups on 
silicon and an intense singlet at 0.98 ppm attributable to the methyls of the t-butyl 
group. The 13C-NMR spectrum showed two signals at -5.72 and -5.68 ppm relative to 
the two methyls on silicon and a signal at 25.8 ppm of t-butyl group. Further 
confirmation comes from the GC-MS where is present a peak at m/z = 359, due to the 
loss by fragmentation of the t-butyl group. 
The protected photoadduct 7 was then methylated using a hindered base such as 
sodiobis(trimethylsilyl)amide (NaHMDS) at -78 °C and subsequent methylation with 
CH3I in hexamethylphosphoroamide (HMPA). Compound 8 was obtained as epimeric 
mixture at C(13) and this mixture was reacted as such in the subsequent steps, because 
the stereochemistry of stereogenic center will be established in the desired manner 
during the subsequent reaction of aldolic condensation necessary for the formation of 
the bicyclo[2.2.2]octane system. The formation of methylated photoadduct 8 was 
confirmed by 1H-NMR spectra of both epimers through the appearance of a doublet at 
0.97 ppm and 1.22 ppm, corresponding to the three protons of the added methyl. The 
analysis of the GC-MS of both epimers showed retention times slightly different and a 
m/z value = 373 relative to the loss of the t-butyl group. 
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2.1.4 Synthesis of compounds 11a and 11b 
 
Before the oxidative cleavage of the exocyclic double bond the methylated 
photoadduct 8 was converted into the acetal 9 (Figure 60). The reaction was carried out 
by treating the intermediate 8 with ethylene glycol, benzene and TsOH and removing 
the water formed with a Dean-Stark apparatus. A mixture epimeric at C(13) was 
obtained. The formation of compound 9 was confirmed by the IR spectra of both 
epimers by the disappearance of the band relative to the stretching of C=O. GC-MS 
confirmed the obtaining of two compounds with near retention times and having a value 
corresponding to the molecular ion of m/z = 474. 
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Figure 60: Synthesis of the intermediate 10 
 
The epimeric mixture 9 was subjected to oxidative cleavage with OsO4 and NaIO4 to 
give the cyclobutanone 10 (Figure 60), a mixture of epimers at C(13) with different Rf. 
The 1H-NMR spectra showed the disappearance of the signals at 4.98 ppm and 5.31 
ppm of the two methylene protons of the C(16). The IR spectra showed the presence of 
the band relative to the stretching of C=O to 1771 cm-1. Finally, GC-MS showed the 
presence of two peaks with a molecular ion m/z = 476 with retention times close to each 
other. The cyclobutanone 10 was then reduced with NaBH4 in Et2O/MeOH and 
afterwards treated with a mixture of THF/2N HCl at 80 °C to give compound 11 (Figure 
61) in an approximate 80:20 endo/exo ratio. In this step, the carbonyl group was 
deprotected, the resulting hydroxy ketone underwent a retro-aldol reaction, which was 
followed by a new aldol reaction which finally led to compound 11. 
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Figure 61: Synthesis of epimeric mixture 11a and 11b 
 
The formation of ketols 11 has been confirmed by IR spectra in which a signal is 
present at 1715 cm-1 attributable to the stretching of C=O. In addition GC-MS showed 
two peaks with a molecular ion m/z = 320 and with very close retention times. 
 
 
2.1.5 Synthesis of (+)-2-deoxyoryzalexin S 1 
 
Epimers 11 were treated with p-toluenesulfonic acid, at 80 °C, in toluene at reflux, 
giving the transposition product 12 characterized by the bicyclo[3.2.1]octane system 
(Figure 62). 
H
HO H
OH
O
H
HO H
O
H
HO H
TsOH,
toluene
80°C
1)BF3Et2O
2)HSCH2CH2SH
yield 74% yield 84%
11 12 13
endo / eso = 8 / 2
SS
 
 
Figure 62: Synthesis of compound 13 
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The formation of 12 was confirmed by the presence in the 1H-NMR spectrum of the 
signal of the olefinic proton at 5.31 ppm. The IR spectrum showed the signal at 1728 
cm-1 relative to the stretching of C=O and from GC-MS a molecular ion peak at m/z = 
302 was obtained. Thioacetalization of 12 with ethanedithiol and BF3∙Et2O at 0°C 
afforded then compound 13, which was transformed into 1 by the action of Raney-Ni in 
EtOH at 60°C (Figure 63). 
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Figure 63: Synthesis of (+)-2-deoxyoryzalexin S 1 
 
The formation of the compound 13 was confirmed by the disappearance in the IR 
spectrum of the signal at 1728 cm-1 relative to the C=O. The 1H-NMR spectrum showed 
the signal of the olefinic proton at 5.0 ppm, and finally GC-MS analysis revealed the 
peak of the molecular ion at m/z = 378. The formation of the final product 1 was 
confirmed by GC-MS which showed a peak with the molecular ion at m/z = 288. In the 
1H-NMR spectrum is present a signal of an olefinic proton at 4.93 ppm. 
 
 
2.1.6 The key step of the (+)-2-deoxyoryzalexin S synthesis. 
 
The key step of this synthesis is the acid-catalyzed transposition of a 6-hydroxy-
bicyclo[2.2.2]octane-2-one intermediate to the bicyclo[3.2.1]octane system typical of 
stemarane compounds. On the basis of the stereoelectronic requirements of the 
bicyclo[2.2.2]octane to bicyclo[3.2.1]octane rearrangement and on the endo/exo 6-
hydroxy-bicyclo[2.2.2]octan-2-one equilibrium, under the reaction conditions adopted, 
for the rearrangement we propose the rationale reported in figure 64. 
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Figure 64: Acid-catalyzed rearrangement mechanism proposed 
 
This equilibrium is due to an unfavorable 1,3 boat-axial interaction experimented in 
the exo epimer by the pseudo-axially oriented hydroxyl group. The protonated exo 
hydroxyl compound act as the leaving group and the acyl group migration occurs from 
the anti side. The endo epimer does not undergo rearrangement because the carbonyl 
function at C(2) prevents the development of a positive charge on the adjacent bridged 
carbon. Moreover the role of the bridgehead methyl in stabilizing the carbocation 
resulting from the rearrangement was confirmed by the fact that the same experimental 
conditions were applied to known 212 no reaction occurred. 
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2.2 Retrosynthetic analysis for stemod-(13)-en-(19)-ol. 
 
For the obtaining of target stemod-(13)-en-(19)-ol 19 ketol 11a, an intermediate of 
the (+)-2-deoxyoryzalexin S synthesis (Scheme 17), was chosen as starting material. 
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Scheme 17: Retrosynthetic approach to stemod-(13)-en-(19)-ol 
 
2.2.1 Synthesis of stemod-(13)-en-(19)-ol 
 
The thioketalization was carried out on 11a whose HO-C(12) is correctly oriented for 
the final reaction of transposition. Thus endo 11a was reacted with ethanedithiol and 
BF3∙Et2O at 0 °C to give the thioacetal 17 (Figure 65). 
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Figure 65: Synthesis of compound 17 
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The formation of thioacetal 17 was confirmed by the disappearance, in the IR 
spectrum, the signal at 1715 cm-1 relative to the stretching of C=O. 
In the 1H-NMR spectrum two doublets at 3.82 ppm and 3.45 ppm relative to the AB 
system of –CH2OH group, and two triplets at 3.38 ppm and 3.15 ppm relative to two 
CH2 directly linked to the two sulfur atoms of the thioacetal group are observed. The 
thioketal 17 was afterwards subjected to desulphurization by treatment with Raney-Ni, 
at 60°C, in absolute EtOH under reflux to give the compound 18 (Figure 66). 
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Figure 66: Synthesis of compound 18 
 
The formation of compound 18 was confirmed by the disappearance, in the 1H-NMR 
spectrum, the two triplets at 3.38 ppm and 3.15 ppm relative to the thioacetal group. In 
addition GC-MS analysis showed a molecular ion peak with m/z = 306. 
Finally, the reaction of trasposition  was carried out by treating compound 18 with 
para-toluensulphonic acid at 80 °C, in anhydrous benzene under reflux. Surprisingly 
along with the expected stemodane compound 19 (+)-2-deoxyoryzalexin S 1 was also 
formed, in ratio 1/1.6 (Figure 67). 
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Figure 67: Rearrangement intermediate 18 
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Stemod-(13)-en-(19)-ol 19 was isolated and characterized. The formation of the 
stemod-(13)-en-(19)-ol 19, was confirmed by the appearance in the 1H-NMR spectrum 
of a signal at 5.5 ppm relative to the olefinic proton at C-(12). In addition GC-MS 
analysis shows a molecular ion peak with m/ z = 288. 
 
 
2.2.2 A hypothesis for the formation of the stemarane system. 
 
From the results obtained, we proposed the following hypothesis concerning the 
formation of the stemarane system (figure 68). 
 
H OH H
OH
 TsOH, 
80°C, benzene
48h
H
OH2
endo exo
H
H OH2
+
H
Stemodane skeleton
B,C,D rings
Stemarane skeleton
B,C,D rings  
 
Figure 68: Mechanism hypothesis 
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To confirm this hypothesis we submitted a secondary chiral alcohol, (R)-(-)-sec-
butanol, to the same reaction conditions (figure 69). After 48 hours the analysis of the 
reaction mixture revealed complete recemization of the starting (R)-(-)-sec-butanol. 
 
OH OH OH
+
(R)-(-)-2-butanol (R)-(-)2-butanol (S)-(-)2-butanol
1 : 1
TsOH
anh. benzene
48 h, 80°
 
 
Figure 69 
 
 Having obtained (+)-2-deoxyoryzalexin S 1,  it was thought to confirm the structure 
and the absolute configuration of a compound isolated in Chile by Garbarino from 
plants of the genus Calceolaria, to which to the structure of 2-deoxyoryzalexin S 15 had 
been attributed (Figure 70) . 
 
H
HO H
H
H
HO
1 
(+)-2-deoxyoryzalexin S
15 
(-)-2-deoxyoryzalexin S  
 
Figure 70 
 
The NMR data recorded by us for the (+)-2-deoxyoryzalexin S 1 and those reported 
in literature for Garbarino for compound 15 were therefore compared. We can observe, 
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on table 1, the differences in the 13C NMR data regarding C(5), C(7), C(8), C(11), 
C(12), C(15), and C(16). 
 
Position 
(+)-2-deoxyoryzalexin S a 2-deoxyoryzalexin S b 
δC type δH (J in Hz) 
δC 
type 
δH (J in Hz) 
1 32.0, CH2 
d 
1.75-1.62, m 
31.8 
  
1.22-1.12, m   
2 18.4, CH2 
1.57-1.52, m 
18.3 
  
1.48-1.41, m   
3 35.6, CH2 
1.86-1.79, m 
36.3 
  
0.95-0.85, m   
4 38.7, C e   38.5 d   
5 50.2, CH 1.27-1.22, m 49.4   
6 22.09, CH2 
1.65-1.57, m 
21.5 
  
1.36-1.31, m   
7 31.8, CH2 
d 
1.75-1.62, m 
35.3   
1.22-1.12, m 
8 44.4, CH 2.01-1.93, m 42.2   
9 51.1, C  51.4   
10 38.3, C e   38.2 d   
11 30.0, CH2 
1.66-1.60, m 
24.5   
1.49-1.43, m 
12 43.3, CH 2.19 t(4.4) 41.7   
13 138.9, C   138.6   
14 123.9, CH 4.94 pd (4.3) 123.4 4.77 bs 
15 33.4, CH2 
1.65-1.57, m 
34.2 
  
1.54-1.44, m   
16 32.4, CH2 
1.51-1.44, m 
28.1 
  
1.44-1.37, m   
17 22.12, CH3 1.62 pt(1.3) 21.8 1.62 d (1.0) 
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18 27.2, CH3 0.95 s 26.7 0.97 s 
19 65.5, CH2 
3.80 d (10.9) 
65.0 
3.78 d (11.0) 
3.42 dd (10.5, 1.0) 3.38 d (11.0) 
20 17.9, CH3 0.93 s 18.1 0.93 s 
 
Table 1: NMR Spectroscopic Data for (+)-2-deoxyoryzalexin S and 2-deoxyoryzalexin S. 
a
 
1
H and 
13
C NMR at 400.13 and 100.61 MHz, respectively; δ in ppm relative to the residual solvent 
peak of CDCl3 at 7.26 and 77.0 ppm for 
1
H and 
13
C respectively. 
b 1
H and 
13
C NMR at 250 
and 63 MHz, respectively; δ in ppm relative to TMS as internal standard. 
 
(+)-2-deoxyoryzalexin S acetyl derivative 14 has also been synthesized and 
characterized. The data of compound 14 were compared with the data of the acetyl 
derivative 16 prepared by Garbarino from 15 (Figure 71). 
 
H
AcO H
H
H
AcO
14 
(+)-2-deoxyoryzalexin S
acetyl derivative
16 
(-)-2-deoxyoryzalexin S
acetyl derivative  
 
Figure 71 
 
 The results (table 2 and 3) showed, also in this case, that the two products are not 
identical. Not identical, are in fact the spectra of 1H and 13C-NMR, the melting points 
and the absolute [α]20D value. Differences was found particularly in the 
13C NMR of 
C(5), C(7), C(8), C(11), C(12), C(15), and C(16).  
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 [α]20D  Melting point 
14 + 58.2 118.2-119.7°C 
16 -17.02 96-97°C 
 
Table 2: Melting points and specific rotations of acetyl derivatives 14 and 16 
 
Position 
Compound 14 a Compound 16 b 
δC type δH (J in Hz) δC type δH (J in Hz) 
1 31.9, CH2 
d 
1.76-1.63, m 
31.7 
  
1.23-1.12, m   
2 18.4, CH2 
1.58-1.50, m 
18.4 
  
1.47-1.40, m   
3 36.3, CH2 
1.76-1.69, m 
36.1 
  
0.99-0.89, m   
4 37.2, C    36.8 d   
5 50.2, CH 1.27-1.22, m 49.4   
6 22.1, CH2 
1.66-1.60, m 
21.7 
  
1.41-1.35, m   
7 31.8, CH2 
d 
1.75-1.63, m 
36.3   
1.23-1.12, m 
8 44.3, CH 2.01-1.96, m 42.2   
9 51.1, C  51.4   
10 38.8, C    38.5 d   
11 29.9, CH2 
1.65-1.60, m 
24.6   
1.48-1.43, m 
12 43.3, CH 2.19 t(4.4) 41.8   
13 138.9, C   138.4   
14 123.9, CH 4.94 pd (3.2) 123.2 4.77 bs 
15 33.4, CH2 
1.65-1.58, m 
34.2 
  
1.52-1.44, m   
16 32.2, CH2 1.52-1.45, m 28.1   
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1.44-1.37, m   
17 22.1, CH3 1.62 pt(1.3) 22.0 1.63 d (1.0) 
18 27.7, CH3 0.93 s 27.3 0.93 s 
19 67.2, CH2 
4.27 d (10.5) 
66.8 
4.28 d (11.0) 
3.87 d (10.5) 3.84 d (11.0) 
20 17.9, CH3 0.96 s 18.0 1.02 s 
21 171.6, C   171.1   
22 21.2, CH3 2.04 s 21.0 2.03 s 
 
Table 3: NMR Spectroscopic data for acetyl derivatives of  (+)-2-deoxyoryzalexin S 14 and 2-
deoxyoryzalexin S 16. 
a
 
1
H and 
13
C NMR at 400.13 and 100.61 MHz, respectively; δ in ppm 
relative to the residual solvent peak of CDCl3 at 7.26 and 77.0 ppm for 
1
H and 
13
C 
respectively. 
b 1
H and 
13
C NMR at 250 and 63 MHz, respectively; δ in ppm relative to TMS 
as internal standard. 
 
Moreover, the structure of the (+)-2-deoxyoryzalexin S acetyl derivative 14 was 
confirmed by X-Ray crystallographic analysis using synchrotron radiation data 
collected at ELETTRA (XRD-1 beamline) by Dr. Doriano Lamba, C.N.R., Area 
Science Park – Basovizza, Trieste (Figure 72). 
 
Figure 72: X-Ray structure of A. Thermal ellipsoids are shown at the 50% probably level 
 
Because Garbarino had originally speculated that Calceolaria diterpenes could have 
a stemodane or stemarane skeleton, opting, then, for the latter, as a result of non-identity 
of the (+)-2-deoxyoryzalexin S acetyl derivative  14 with the product isolated from 
Calceolaria, we decided to prepare from 11a an intermediate of (+)-2-deoxyoryzalexin 
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S 1 synthesis, stemod-(13)-en-(19)-ol 19 which differs from 1 in the C/D ring system 
(Figure 73). In this way it would be possible to check if the structure of the product 
isolated by Garbarino from Calceolaria. 
 
HHO
H
HHO
H
HHO
H
OH
O
1
(+)-2-deoxyoryzalexin S
19 
(+)-stemod-(13)-en-(19)-ol
11a
ketol endo
 
 
Figure 73. 
 
Comparing the 13C-NMR spectrum of the compound 19 with that of the compound 
isolated from Garbarino from Calceolaria it could be established, however, the non-
identity of the two compounds (Table 4). 
 
HHO
H
19 
(+)-stemod-(13)-en-(19)-ol  
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19 15 
142.11 138.8 
117.05 123.3 
65.82 68.1 
50.82 51.5 
48.55 49.6 
46.83 42.3 
42.97 41.7 
38.45 38.5 
38.09 37.1 
37.33 36.4 
35.66 36.1 
35.22 34.1 
32.59 31.8 
31.75 28.1 
29.51 27.3 
27.66 24.7 
22.19 22.1 
21.37 21.7 
20.76 18.4 
18.45 18.2 
 
Table 4: left:19) 
13
C-NMR (ppm) of stemod-(13)-en-(19)-ol and 15) 
13
C-NMR (ppm) of the 
compound isolated from Calceolaria (-)-2deoxyoryzalexin S. right: Structure of stemod-
(13)-en-(19)-ol and of (-)-2deoxyoryzalexin S. 
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2.3 Retrosynthetic approach to (-)-kaurene 
 
For the obtaining of target (-)-kaurene, (-)-abietic acid 21 from which the chiron 
enone 6 was derived (Scheme 18), was chosen as starting material, and thus as chiral 
template. 
 
H
H
HO2C
21
(-)-abietic acid
O
HMeO2C
26
O
HMeO2C
27
H H
HMeO2C
29
H
OO
O
HMeO2C
31
O
OH
(-)-kaurene
H
 
 
Scheme 18: Retrosynthetic approach to (-)-Kaurene 
 
 
2.3.1 From (-)-abietic acid 21 to the chiron 6 
 
In the first step of the synthesis, the carboxyl group of (-)-abietic acid 21 was 
methylated (figure 74). The methylation reaction was carried out under basic conditions 
using dimethyl sulphate, to give 98% of  methyl abietate 22. The formation of methyl 
abietate 22 was confirmed by the presence in the 1H-NMR spectrum of a singlet at 3.6 
ppm, relative to the ester group. The 13C-NMR spectrum showed a signal at 179.1 ppm 
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relative to same group. The IR spectrum showed a band at 1722 cm-1 attributable to an 
ester carbonyl. Finally, as further confirmation, GC-MS analysis gave the molecular 
peak at m/z = 316. 
 
H
H
HO2C
H
H
MeO2C
21 22
LiOH, DMF
Me2SO4
yield 98%
(-)-abietic acid
acetic acid
yield 42%
H
H
MeO2C
Br
Br
23
33% HBr
 
Figure 74. 
 
Methyl abietate 22 was then treated with a solution of 33% hydrobromic acid in 
acetic acid to give 42% of dibromo derivative 23 (figure 75). The formation of 
compound 23 was confirmed by the disappearance of the signals related to the olefinic 
protons in the 1H-NMR spectrum and by the absence, in the 13C-NMR spectrum, of 
signals in the region 140-115 ppm relative to the two carbon-carbon double bonds. The 
IR spectrum showed a band at 1722 cm-1 attributable to an ester carbonyl. 
The dehydrobromination of 23 was carried out with lithium hydroxide in 
dimethylformamide at 80°C, to give the diene 24 (figure 75). The formation of diene 24 
was confirmed by the presence in the 13C-NMR spectrum of signals at 138.8, 128.4, 
126.2, 120.9 ppm relative to the two tetrasubstituted double bonds. The IR spectrum 
showed a band at 1720 cm-1 attributable to an ester carbonyl. Finally, as further 
confirmation, GC-MS analysis gave the molecular peak at m/z =316. 
 
H
H
MeO2C
Br
Br
23
LiOH, DMF
HMeO2C
24
1) O3, CH2Cl2,
-78°C
2) Zn, CH3COOH
O
HMeO2C
25
yield 72%
yield 48%
 
Figure 75 
 
RESULTS AND DISCUSSION 
 
88 
 
The diene 24 was subjected to ozonolysis, using a stream of ozone in 
dichloromethane at -78°C; the ozonide was then reacted with zinc in acetic acid, to give 
48% of β,γ-enone 25 (figure 75). The formation of compound 25 was confirmed by the 
presence in the 13C-NMR spectrum of a signal at 211.5 ppm relative to the unconjugated 
carbonyl function. The latter was also observed in the IR spectrum which showed a 
band at 1715 cm-1. Finally, as further confirmation, GC-MS analysis gave the molecular 
peak at m/z = 290. 
Isomerization of β,γ-enone 25 with hydrochloric acid in methanol gave 88% of α,β-
enone 26 (figure 76). The formation of compound 26 was confirmed by the presence in 
the 1H-NMR spectrum of a singlet at 5.86 ppm relative to the olefinic proton at C(9). 
The 13C-NMR spectrum showed a signal at 199.6 ppm relative to the carbonyl function 
of a α,β-unsatured ketone. The IR spectrum showed a band at 1660 cm-1 attributable to 
the carbonyl function of a α,β-unsatured ketone. Finally, as further confirmation, GC-
MS analysis gave the molecular peak at m/z = 290.  
 
O
HMeO2C
25
O
HMeO2C
26
HCl, MeOH
Hyield 88%
 
 
Figure 76 
 
Photoaddition of allene to 26 at -78°C proceeded from the β-face and gave the 
expected cyclophotoadduct 27 with a yield of 67% (figure 77)1,2. The formation of 
compound 27 was confirmed by the presence in the 1H-NMR spectrum of a singlet at 
4.84 ppm relative to the proton of the exocyclic double bond. The 13C-NMR spectrum 
showed the signals at 142.1 ppm and at 210.5 ppm relative to the olefinic carbon C(15) 
and C(13). The IR spectrum showed a band at 1715 cm-1 attributable to the carbonyl 
function. Finally, as further confirmation, GC-MS analysis gave the molecular peak at 
m/z =330. 
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O
HMeO2C
26
H
O
HMeO2C
27
H
HMeO2C
28
H
O
O
Allene, -78°C
THF, hv HOCH2CH2OH
yield 67% TsOH
yield 95%
 
 
Figure 77 
 
Before the oxidative cleavage of the exocyclic double bond, compound 27 was 
converted into the acetal 28 with a yield of 95%, by standard methods (Figure 77). The 
reaction was carried out by treating the intermediate 7 with ethylene glycol, benzene 
and TsOH, removing the water formed with a Dean-Stark apparatus. The formation of 
compound 28 was confirmed by the IR spectra by the disappearance of the band relative 
to the stretching of C=O. In the 1H-NMR spectrum of a multiplet at 3.80-4.00 ppm 
relative to the four acetal protons was present. The 13C-NMR spectrum showed the 
signals at 64.1 ppm and at 64.3 ppm relative to the OCH2CH2O. Moreover the 
13C-
NMR spectrum showed the disappearance of a signal at 210.5 relative to the C=O in the 
compound 7, and the presence of the signal at 110.4 relative to the protected carbonyl 
C(13). GC-MS gave the molecular peaks at m/z = 376. 
Acetal 28 was converted into the cyclobutanone 29 by the action of OsO4 and NaIO4 
(figure 78). The formation of compound 29 was confirmed by the IR spectra by the 
presence of the band relative to the stretching of C=O at 1782 cm-1. 
 
HMeO2C
28
H
O
O
yield 76%
HMeO2C
29
H
OO
O
OsO2, NaIO4
 
 
Figure 78 
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The carbonyl function of the compound 29 was then converted, by reduction, into the 
hydroxyl compound 30 (figure 79), which was used in the next step without 
purification. Treatment of 30 with a 2:1 mixture THF/2N HCl under reflux for 24 h 
gave hydroxyl ketone 31a and 31b in a ca. 9:1 ratio. 
 
HMeO2C
29
H
OO
O
NaBH4,
MeOH
HMeO2C
30
H
OHO
O
HMeO2C
31a + 31b
R1 = H        R1 =OH
R2 =OH      R2 = H
O
THF, 2H HCl
reflux, 24h
yield 85%
R2R1
H
 
Figure 79 
 
The 1H-NMR spectrum of 31a and 31b showed the signals related to the protons of 
the hydroxyl group at 4.12 ppm and 4.20 ppm, respectively. The 13C-NMR spectrum 
showed the signals at 55.1 ppm and at 54.7 ppm relative to C(15). Moreover the IR 
spectra showed the presence of the band relative to the stretching of C=O at 1720 cm-1. 
In accordance with precedent cases140, the major epimer was attributed the structure 
31a, which the HO-C(13) is endo-configurated. The assignment was confirmed by 
comparing the 13C chemical shifts of the HO-C(13) of 31a (69.1ppm) and 31b (65.5 
ppm): these values are diagnostic in that the signal of the HO-C(13) in the exo-epimer 
appears at higher field. The same Δδ is displayed by the C(11)-atom in 31a and 31b the 
C(11)- and C(13)-atoms in 30b seem, therefore, to be in sterically more crowded 
environment than the corresponding C-atoms in 31a.  
Unfortunately when compound 31, dissolved in benzene, was refluxed in the 
presence of TsOH no reaction occurred. It appears, therefore, that this rearrangement 
must be encouraged by some means like for instance the presence of an exo olefinic 
bond. We hope to be able to prove in the near future this hypothesis.  
 
 
CONCLUSIONS 
91 
 
Conclusions 
 
In the frame of this Ph.D. work the first synthesis of (+)-2-deoxyorizalexin S from 
(+)-podocarpic acid was achieved. (+)-2-deoxyoryzalexin S was characterized also as its 
acetyl derivative. The structure of the latter was confirmed by X-ray crystallographic 
analysis. Comparison of the data of the (+)-2-deoxyoryzalexin S and its acetyl derivative 
with those reported in letterature by Garbarino did not confirm the structure of (-)-2-
deoxyoryzalexin S originally assigned to the diterpenoid isolated from Chilean 
Calceolaria species. 
(+)-stemod-(13)-en-(19)-ol was then synthesized from an intermediate of the 
synthesis of (+)-2-deoxyoryzalexin S. (+)-stemod-(13)-en-(19)-ol was characterized as 
the acetyl derivative.  Comparison of the data of (+)-stemod-(13)-en-(19)-ol and its 
acetyl derivative with those reported in letterature by Garbarino did not confirm the 
structure of (-)-2-deoxyoryzalexin S. 
Intermediates of this work will be tested to evaluate their phytoalexin activity 
particularly those possessing a stemarane skeleton. 
After having concluded this part of the work, we used the same methodology in order 
to get the kaurane system. Starting from pre-formed system of (+)-abietic acid, an 
advanced intermediate was obtained, which hopefully will allow us to get the kaurane 
system in the near future. 
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Experimental Part 
 
4.1 Materials and methods 
 
All solvents were evaporated to dryness under vacuum. All solvents were anal. 
grade. All reagents and anhydrous solvents were ALDRICH, they were used without 
further purification if not indicated. 
TLC: Merck silica gel 60 F254. Column chromatography (CC): silica gel 60, 70-230 
mesh ASTM. Melting point: Mettler-FP-61 apparatus (uncorrected).  
IR Spectra: FT-IR spectrometer, Shimadzu-8400S IR scattering, NaCl cell; in cm-1. 
 1H- and 13C NMR spectra (compound 8): Bruker AC 300  at 300.13 and 75.48  
MHz, respectively; δ in ppm relative to the residual solvent peak of C6D6 at 7.15 and 
128.02 ppm and CDCl3at 7.26 and 77.0 ppm for 
1H- and 13C, respectly. 
1H- and 13C NMR spectra: Brucker AVANCE 400 at 400.13 and 100.61 MHz, 
respectly; δ in ppm relative to the residual solvent peak of C6D6 at 7.15 and 128.02 ppm 
and CDCl3at 7.26 and 77.0 ppm for 
1H- and 13C, respectly; J in Hz. 
HPLC analysis: Shimadzu SCL-10 A VP; RID detector (RID 10-A) and UV-VIS 
detector (SPD 10-A). HPLC experiments were performer at room temperature. 
Analytical columns, EC 250/4 Nucleosil 100-5, EC 250/4 Nucleodur 100-5; flow rate of 
0.8 mL/min; semipreparative column, VP 250/10 Nucleodur 100-5; flow rate of 6 
mL/min.  
GC-MS analysis: Shimadzu  GCMS-QP5000, (EquityTM-5 capillary column, n° 
32809-02B, 30 m x 0.25 mm,  film thickness 0.25 μm). 
Optical rotations: DIP 370 Jasco digital polarimeter. 
HRESIMS spectra: Micromass Q-TOF Micromass spectrometer (Waters) in the 
electrospray-ionization mode. 
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4.2 Abbreviations and notes 
 
TLC : thin layer chromatography 
CC : column chromatography 
r.t.: room temperature 
s.s.: saturated solution 
THF : tetrahydrofuran 
TsOH = p-toluenesulfonic acid 
TBDMSCl = t-butyl dimethyl silyl chloride 
m.p. = melting point 
brine = NaCl saturated solution 
DEG = diethylenglicol 
HMPA= hexamethylphosphoramide 
 
NMR: J = coupling constant in Hz; s = singlet; d = doublet; t = triplet;  m = multiplet; 
b = broad, dd = doublet of doublets, ddd = doublet of doublets of doublets, dtd = 
doublet of triplet of doublets, o = overlapping signals. GC-MS: peak intensity expressed 
in % in round bracket (relative to base peak). 
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4.3 Preparations 
 
Synthesis of 2 from (+) podocarpic acid 20: 
 
OH
H
CO2H
OCH3
H
CO2CH3
(CH3)2SO4
NaOH
yield 90%
20 
(+) podocarpic acid
2
 
 
To a solution of (+)-podocarpic acid 20 (20 g, 73 mmol) in aqueous EtOH50% (300 
mL), NaOH (9 g, 225 mmol) was added, until achieving a basic pH. After that dimethyl 
sulphate (20.5 mL, 216 mmol) was added dropwise through dropping funnel. The 
mixture was stirred at reflux (for 48 h) until TLC (eluent: AcOEt/hexane = 3/7) showed 
the disappearance of the starting material. 
The mixture was cooled to r.t. and washed with Et2O, brine, dried over anhydrous 
Na2SO4, filtered, and evaporated to dryness under reduced pressure.  
The residue obtained, was crystallized from hexane, giving 2 (19.8 g, 65.6 mmol, 
yield 90%). 
 
m.p.:    124.3 - 126.9°C. 
[α]D :    +129 (c = 3.0 g/100 mL, CHCl3). 
IR (CHCl3): 2951, 1719 cm
-1. 
¹H-NMR (CDCl3): 1.02-1.14 (m, 1H), 1.03 (s, 3H), 1.27 (s, 3H), 1.34-1.65 (m, 3H), 
1.87-2.30 (m, 5H), 2.67-2.89 (m, 2H), 3.66 (s, 3H), 3.77 (s, 3H), 
6.65-6.98 (m, 3H). 
¹³C-NMR (CDCl3): 20.2, 21.3, 23.1, 28.7, 31.4, 37.8, 38.8, 39.6, 44.2, 51.4, 53, 55.4, 
111.3, 111.4, 127.8, 130, 149.5, 157.9, 178. 
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GC-MS: (tR 10.6)   m/z = 302 (M
+ ,47), 287 (4), 243 (2), 228 (20), 227 (100), 213 
(1), 199(3), 185 (7), 173 (13), 171 (20), 161 (15), 159 (10), 147 (15), 
134 (11), 128 (9), 121 (12), 115 (11), 91 (10), 77 (6), 69 (6), 59 (6), 55 
(10), 53 (4). 
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Synthesis of 3 from 2: 
 
OCH3
H
CO2CH3
OCH3
H
CH2OH
LiAlH4
anh. THF
yield 99%
2 3  
 
To a solution of 2 (19.8 g, 65.6 mmoli) in anhydrous THF (396 mL), LiAlH4 (2.50 g, 
65.8 mmol) was added. The mixture was stirred under an Ar atmosphere, until TLC 
(eluent: AcOEt/hexane = 3/7) showed the disappearance of the starting material (12 h). 
The excess hydride was destroyed carefully with drops of H2O at 0 °C and then a 2N 
HCl solution was added to obtained a neutral solution. 
The mixture was extracted with Et2O, and the organic layer washed with brine, dried 
over anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. 
The residue obtained, was crystallized from hexane/Et2O, giving 3 (18 g, 65.7 mmol, 
yield 99%). 
  
m.p.:    89.2 – 90.8 °C. 
[α]D :    +67 (c= 2.0 g/100 mL, CHCl3) 
IR (CHCl3): 2930, 1261 cm
-1.  
¹H-NMR (CDCl3): 1.06 (s, 3H), 1.19 (s, 3H), 1.26-2.01 (m, 9H), 2.27-2.31 (m, 1H), 
2.71-2.92 (m, 2H), 3.52-3.88 (m, 2H), 3.78 (s, 3H), 6.65-6.97 (m, 
3H). 
¹³C-NMR (CDCl3): 19.2, 19.4, 25.8, 27, 30.3, 35.4, 38.1, 39, 51.4, 55.3, 65.2, 110.6, 
111.1, 127.2, 130.0, 151.1, 157.8.  
GC-MS: (tR 11.1) m/z  = 274 (M
+, 80), 272 (6), 259 (10), 241 (42), 229 (9), 
201 (19), 199 (12), 187 (12), 185 (16), 174 (11), 173 (43), 171 
(29), 161 (93), 159 (33), 158 (20), 148 (14), 147 (100), 141 (11), 
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135 (19), 134 (18), 129 (17), 128 (23), 121 (43),  115 (29), 91 
(28), 81 (19), 77 (16), 55 (32), 53 (10). 
HPLC: eluent: AcOEt/hexane =15/85, flow: 0.8 mL/min, tR 16.7 min. 
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Synthesis of 4 from 3: 
 
OCH3
H
CH2OH
OCH3
H
TBDMSO
TBDMSCl
imidazole 
anh. THF
yield 95%
3 4  
 
To a solution of 3 (18.0 g, 65.7 mmol) in anhydrous THF (69.2 mL), tert-
butyldimethylsilyl chloride (TBDMSCl, 11.7g, 78.0 mmol) and imidazole (5.75 g, 84.5 
mmol) were added. 
The mixture was stirred at r.t. until TLC (eluent: AcOEt/hexane = 3/7) showed the 
disappearance of the starting material  (14 h). n-Hexane was added, the suspension 
filtered through Celite, the organic phase evaporated, and the residue purified by CC 
(AcOEt/n-hexane, 2.5:97.5) to give 4 (24.3 g, 62.5 mmol, yield 95%). 
 
m.p.:    52.9-53.9 °C. 
[α]D :    +50 (c = 1.47 g/100 mL, CHCl3) 
IR (CHCl3): 2930, 1250, 1092 cm
-1. 
¹H-NMR (CDCl3): 0.05-0.06 (d, 6H), 0.92 (s, 9H), 1.01 (s, 3H), 1.21 (s, 3H), 1.44-
1.49 (m, 2H), 1.60-1.76 (m, 3H), 1.85-1.89 (m, 1H), 1.96-2.03 
(m, 1H), 2.26-2.30 (m, 1H), 2.70-2.91 (m, 2H), 3.50-3.53 (d, 1H), 
3.70-3.73 (d, 1H), 3.79 (s, 3H), 6.66-6.98 (m, 3H). 
¹³C-NMR (CDCl3): 157.6, 151.2, 129.7, 127.3, 110.7, 110.3, 65.2, 55.2, 50.9, 39.0, 
38.8, 37.9, 35.5, 30.2, 27.4, 25.9, 25.6, 19.4, 19.0, 18.2, -5.5, -5.6. 
GC-MS: (tR 13.3)  m/z = 388 (M
+ , 21), 331 (25), 255 (28), 241 (18), 199 
(12), 185 (37), 173 (20), 171 (13), 161 (51), 159 (17), 147 (40), 
121 (14), 103 (16), 95 (14), 89 (17), 83 (10), 81 (12), 75 (100), 73 
(47), 59 (11), 55 (16).  
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Synthesis of 5 from 4: 
 
OCH3
H
TBDMSO
O
H
HO H
1) Li, NH3,
t-BuOH,
anh. THF
2) HCl
yield 57%
4 5  
 
In a three neck flask equipped with a mechanical stirring, ammonia (600 mL) at -
78°C under Ar was condensed. Then anhydrous THF (600 mL), t-BuOH (14.5 mL) and 
Li (10 g, 1.43 mol) were added under stirring. A solution of 4 (23 g, 59.3 mmol) was 
then added to the mixture, kept under stirring and at -50°C, until TLC (eluent: 
Et2O/hexane = 2.5/7.5) showed the disappearance of the starting material  (7 h). Then, 
absolute EtOH was added up to solution decolouration.  
After evaporation of the ammonia at r.t., water (142 mL), MeOH (56 mL) and 6N 
HCl solution were added, allowing the mixture to stir overnight. The mixture wae then, 
neutralized with a NaHCO3, and the organic layer extracted with Et2O, washed with 
brine, dried on Na2SO4 and concentrated under reduced pressure. 
The residue obtained, was first purified by CC (eluent: AcOEt/hexane = 30/70) and 
then crystallized (distilled Et2O /AcOEt = 1/1) giving α,β-unsatured ketone 5 (8.9 g, 
34.0 mmol, yield 57%). 
 
m.p.:    112.4-113.3°C. 
[α]D :    -32 (c = 2.989 g/100 mL, CHCl3) 
IR (CHCl3): 2934, 1661 cm
-1. 
¹H-NMR (CDCl3): 0.62-0.92 (m, 3H), 0.75 (s, 3H), 0.92 (s, 3H), 1.01-1.60 (m, 9H), 
1.86-2.00 (m, 4H), 2.16-2.27 (m, 1H), 3.27-3.31 (d, 1H), 3.56-
3.60 (d, 1H), 5.86 (s, 1H). 
¹³C-NMR (CDCl3): 201.4, 176.1, 119.6, 65.0, 53.6, 40.8, 39.2, 36.7, 35.7, 35.5, 35.1, 
34.3, 29.3, 26.8, 22.0, 21.4, 18.3.   
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GC-MS: (tR 25.9) m/z = 262 (M
+, 1), 232 (11), 231 (29), 149 (9), 124 (10), 
123 (100), 121 (18), 110 (35), 109 (14), 107 (15), 105 (14), 95 
(10), 93 (13), 91 (21), 81 (14), 77 (12), 67 (12), 55 (26).   
HPLC:  Eluent: AcOEt/hexane = 30/70, flow: 1 mL/min, tR 17.7 min.  
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Synthesis of 6 from 5: 
 
O
H
HO
O
H
HO HH
allene,hv
-78°C
THF
yield 80%
5 6  
 
A Pyrex vessel containing a solution of 5 (6.9 g, 26.2 mmol) in THF (78 mL) was 
cooled to -78°C, and an excess of allene was condensed into it. The vessel was 
irradiated under Ar at -78°C with a 500 W mercury vapor lamp until TLC (eluent: Et2O 
100%)  showed the disappearance of  5 (4 h). The solution was slowly warmed to r.t., 
the solvent evaporated, and the residue purified by CC (eluent: AcOEt/hexane = 3.5/6.5) 
and then crystallized (distilled Et2O /AcOEt) to give the photoadduct 8 (6.3 g, 20.8 
mmol, yield 80%) as a white powder. 
 
m.p.:    174.2-175.8 °C. 
[α]D :    +27 (c = 3.253 g/100 mL, CHCl3) 
IR (CHCl3):  2941, 1686. 
¹H-NMR (CDCl3, 400.13 MHz): 4.91 (1H, pq, J = 2.6 Hz), 4.89 (1H, pq, J = 2.8 Hz), 
3.72 (1H, d, J = 10.8 Hz), 3.47- 3.42 (1H,m), 3.40 (1H, d, J = 10.8 
Hz), 2.79 (1H, dt, Jt = 2.5 Hz, Jd = 17.4 Hz), 2.63 – 2.51 (2H,m), 
2.14 (1H, dddd, J = 0.8 Hz, J = 7.7 Hz, J = 11.5 Hz, J = 19.1 Hz), 
1.95 – 1.25 (12H,m), 1.11(1H, pq, Jd = 4.5 Hz, Jq= 12.7 Hz), 1.03 
(1H, dd, J = 2.9 Hz, J= 12.9 Hz), 0.94 (3H,s), 0.89 (1H, td, Jd = 
4.4 Hz, Jt= 13.7 Hz), 0.81 (3H,s). 
¹³C-NMR (CDCl3, 100.61 MHz): 211.4, 140.8, 109.7 (CH2), 64.8 (CH2), 55.6 (CH), 
49.7, 47.2 (CH), 39.1, 38.5 (CH2), 38.2, 36.5 (CH), 35.4 (CH2), 
31.7 (CH2), 31.6 (CH2), 28.9 (CH2), 26.8 (CH3), 25.3 (CH2), 21.9 
(CH2), 18.1 (CH2), 16.7 (CH3).  
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HRESIMS:  m/z = 325.2159 (calcd for C20H30O2 [M + Na]
+, 325.2144). 
GC-MS:  (tR 25.9) m/z = 262 (M
+, 1), 232 (11), 231 (29), 149 (9), 124 (10), 
123 (100), 121 (18), 110 (35), 109 (14), 107 (15), 105 (14), 95 
(10), 93 (13), 91 (21), 81 (14), 77 (12), 67 (12), 55 (26).   
HPLC: Eluent: AcOEt/hexane = 30/70, flow: 1 mL/min, tR 10.9 min.  
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Synthesis of 7 from 6: 
 
O
H
HO H
O
H
TBDMSO H
TBDMSCl
imidazole 
anh. THF
yield 91%
6 7  
 
To a solution of 3 (5.9 g, 19.5 mmol) in anhydrous THF (20.25 mL), tert-
butyldimethylsilyl chloride (TBDMSCl, 7.7 g, 50.9 mmol) and imidazole (3.0 g, 45.0 
mmol) were added. 
The mixture was stirred at r.t. until TLC (eluent: AcOEt/hexan = 6/4) showed the 
disappearance of the starting material  (5 h). n-Hexane was added, the suspension 
filtered through Celite, the organic phase evaporated, and the residue purified by CC 
(AcOEt/n-hexane, 2.5:97.5) to give 7 (7.2 g, 17.3 mmol, yield 91%) as a white powder. 
 
m.p.:    114.6-116.3 °C. 
[α]D :    +9 (c = 3.11 g/100 mL, CCl4) 
IR (CCl4):   2932, 1697, 1092 cm
-1. 
¹H-NMR (C6D6, 400.13 MHz): 5.02 (1H, q, J = 2.7 Hz), 4.82 (1H, q, J = 2.6 Hz), 3.63 
(1H, d, J = 9.6 Hz), 3.55- 3.49 (1H,m), 3.37 (1H, d, J = 9.6 Hz), 
2.52 (1H, A of ABX2, JAB = 17.5 Hz, JAX2 = 2.7 Hz), 2.47 (1H, 
dd, J = 5.6 Hz, J = 18.8 Hz), 2.30 (1H, B of AYX2, JAB = 17.5 Hz, 
JBY = 3.1 Hz, JBX2 = 2.7 Hz), 2.05 – 1.86 (2H,m), 1.66 – 1.04 ( 
10H, m), 0.99 (9H, s), 0.97 (3H, s), 0.92 – 0.71 (3H, m), 0.64 
(3H, s),  -0.07 (3H, s). 
¹³C-NMR (C6D6, 100.61 MHz): 208.1, 141.7, 109.2 (CH2), 65.1 (CH2), 55.6 (CH), 
49.7, 47.1 (CH), 39.1, 38.6 (CH2), 38.5, 36.5 (CH), 36.0 (CH2), 
31.7 (CH2), 31.5 (CH2), 29.2 (CH2), 27.6 (CH3), 26.2 (3xCH3), 
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25.5 (CH2), 22.2 (CH2), 18.6, 18.4(CH2),  16.5 (CH3), -5.29 
(CH3), -5.33 (CH3). 
HRESIMS:  m/z = 439.3021 (calcd for C26H44O2Si [M + Na]
+, 439.3008). 
GC-MS:  (tR 15.5) m/z = 359 (M
+ - t-butyl) (9), 269 (10), 187 (11), 173 (19), 
159 (12), 145 (12), 131 (13), 119 (12), 105 (16), 89 (22), 75 (100), 
67 (12), 55 (27).  
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Synthesis of 8 from 7: 
 
O
H
TBDMSO H
O
H
TBDMSO H
1)NaHDMS,
 anh. THF 
2)CH3I, HMPA
-78°C
yield 88%
7 8a +8b  
 
A solution of sodium bis(trimethylsilyl) amide (NaHDMS, 17 mL, 1M in THF, 17 
mmol) was added at -78°C to a solution of 7 (7.0 g, 17 mmol) in THF (43 mL). After 1 
h  the resulting sodium enolate was added to a solution of CH3I (2.03 mL, 33 mmol) in 
hexamethylphosphoramide (HMPA, 8.7 mL, 50 mmol). The solution was stirred at -
78°C until TLC showed the disappearance of 7 (4h). 
The mixture was warmed to r.t., neutralized with 2N HCl, diluted with Et2O, washed, 
dried and evaporated. The residue was purified by CC (eluent: AcOEt/hexane = 
2.5/97.5) to give a mixture of 8a and 8b (6.2 g, 14 mmol, 82%, 8a:8b, 3:1; Rf 8a > Rf 
8b). For analytical purposes the mixture was separated by HPLC (AcOEt/hexane = 
1/99; flow 1 mL /min): 
 
(+) - 8a (tR HPLC =11.7 min): white powder. 
 
m.p.:    106.7 – 108.0 °C. 
[α]D :    +21 (c = 3.13 g/100 mL, CCl4) 
IR (CCl4): 2932, 1699 cm
-1. 
¹H-NMR (C6D6, 300.13 MHz): 4.90 (1H, pq, J = 2.6 Hz), 4.81 (1H, q, J = 2.5 Hz), 3.58 
(1H, A of AB, JAB = 9.6 Hz), 3.56 (1H, pq, J = 2.8 Hz), 3.36 (1H, 
B of AB, JAB = 9.6 Hz), 2.66 – 2.45 (2H, m), 2.33(1H, dq, Jd = 
17.4 Hz, Jq = 2.7 Hz), 2.07 – 1.87 (2H, m), 1.66 – 0.68 (27H, m), 
0.64 (3H, s), 0.07 (6H, s). 
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¹³C-NMR (C6D6, 75.48 MHz): 212.5,  142.2, 109.3 (CH2), 64.9 (CH2), 55.9 (CH), 51.2, 
47.0 (CH), 39.4(CH), 39.2, 38.5 , 35.8(CH2), 34.3 (CH2), 32.7 
(CH), 31.8 (CH2), 31.0 (CH2), 29.2 (CH2), 27.5 (CH3), 26.2 
(3xCH3), 22.0 (CH2), 18.6,  18.4 (CH2),  17.6 (CH3), 16.3 (CH3), -
5.29 (CH3), -5.33 (CH3). 
GC-MS: (tR 15.5) m/z = 373 (M
+ - t-butyl), 283 (10), 187 (15), 173 (14), 
159 (12), 145 (15), 131 (10), 119 (15), 105 (17), 89 (25), 81 (18), 
75 (100), 73, 67 (14), 55 (24). 
HRESIMS: m/z = 453.3143 (calcd for C27H46O2Si [M + Na]
+, 453.3165). 
 
(-) – 8b (tR HPLC =15.3 min): white solid. 
 
m.p.:    150.3 - 151.7 °C 
[α]D :    -8.2860, (c = 4.757 g/100 mL, CCl4) 
IR (CCl4): 2932, 1697 cm
-1. 
¹H-NMR (C6D6, 400.13 MHz): 5.07 (1H, q, J = 2.8 Hz), 4.82 (1H, pq, J = 2.6 Hz), 3.64 
(1H, d, J = 9.7 Hz), 3.55 3.50 ( 1H, m), 3.40 (1H, d, J = 9.6 Hz), 
2.51(1H, A of ABX2, JAB = 17.4 Hz, JAX2 = 2.5 Hz), 2.31 (1H, B 
of ABYX2, JAB = 17.4 Hz, JBY = 3.1 Hz,  JBX2 = 2.7 Hz), 1.97 – 
1.84 (2H, m), 1.61 – 1.10 (13H, m), 1.00 (9H, s), 0.99 (3H, s), 
0.94 – 0.71 (3H, m), 0.65 (3H, s), 0.08 (6H, s). 
 ¹³C-NMR (C6D6, 100.61 MHz): 209.9,  141.6, 109.4 (CH2), 65.1 (CH2), 55.2 (CH), 
49.6, 47.1 (CH), 45.5 (CH), 39.0, 38.6 , 36.8(CH), 36.0 (CH2), 
34.2 (CH2), 31.84 (CH2), 31.78 (CH2), 29.1 (CH2), 27.6 (CH3), 
26.2 (3xCH3), 22.3 (CH2), 19.1 (CH3), 18.6,  18.4 (CH2),  16.6 
(CH3),  -5.29 (CH3), -5.32 (CH3). 
GC-MS: (tR 15.5) m/z = 373 (M
+ - t-butyl), 285 (11), 187 (16), 173 (13), 
159 (10), 145 (16), 119 (14), 105 (16), 89 (19), 81 (16), 75 (100), 
73, 67 (13), 55 (23). 
HRESIMS: m/z = 453.3186 (calcd for C27H46O2Si [M + Na]
+, 453.3165). 
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Synthesis of 9 from 8: 
 
O
H
TBDMSO H
H
TBDMSO H
OO
HO(CH2)2OH,
TsOH,
benzene (reflux)
yield 74%
8 9  
 
A solution of 8 (8a + 8b) (6.1 g, 14 mmol) ethane-1,2-diol  (38 mL, 0.55 mmol) and 
TsOH (0.13 g, 0.71 mmol) in benzene (0.60 L) was placed into a two-neck flask fitted 
with a Dean-Stark apparatus, a condenser, and a CaCl2 tube. The mixture was refluxed 
until TLC showed the disappearance of 8 (24 h).  
After cooling to r.t., the mixture was diluted with Et2O, washed with a satured 
NaHCO3 solution, dried, and evaporated. The residue was purified by CC (eluent: 
Et2O/hexane = 2/98) yielded a mixture of  9a and 9b (5.2 g, 11 mmol, 78%, 9a:9b, 1:9; 
Rf 9a > Rf 9b). For analytical purposes the mixture was separated by HPLC 
(AcOEt/hexane = 0.5/99.5; flow 1 mL /min). 
 
(-) – 9a (tR HPLC =7.2 min): white solid. 
 
m.p.:    117.3-118.3 °C 
[α]D :    -42.783 (c = 1.291 g/100 mL, CHCl3) 
IR (CDCl3): 2930, 1213, 1092 cm
-1. 
¹H-NMR (C6D6, 400.13 MHz): 5.51 – 5.47 (1H, m), 5.01 – 4.97 (1H, m), 3.82 (1H, d, 
J=9.6 Hz), 3.58 – 3.43 (5H, m), 2.96 (1H,bs), 2.52 (1H, A of 
ABX2, JAB = 17.3 Hz, JAX2 = 2.4 Hz), 2.46 (1H, B of ABYX2, JAB 
= 17.3 Hz, JBY = 2.8 Hz,  JBX2 = 2.7 Hz), 2.16 – 1.98 (3H, m), 
1.71 – 1.25 (12H, m), 1.11 (3H, m), 1.05 (3H, s), 1.03 – 0.82 
(12H, m), 0.094 (3H, s), 0.091 (3H, s),. 
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¹³C-NMR (C6D6, 100.61 MHz): 144.4 (CH2),  111.4, 109.5 , 65.2 (CH2), 64.4 (CH2), 
63.5 (CH2),  49.2, 47.5 (CH), 47.2 (CH), 39.4(CH), 39.0, 38.7 , 
36.0(CH2), 35.7 (CH2), 32.5 (CH), 32.2 (CH2), 31.1 (CH2), 29.6 
(CH2), 27.7 (CH3), 26.2 (3xCH3), 22.3 (CH2), 20.3 (CH3), 
18.7(CH2),  18.6, 16.5 (CH3),  -5.25 (CH3), -5.31 (CH3). 
GC-MS: (tR 17.9) m/z = 474 [M
+] (7), 329 (13), 205 (9), 113 (100), 100 
(7), 75 (29), 69 (13), 55 (9). 
HRESIMS: m/z = 497.3450 (calcd for C29H50O3Si [M + Na]
+, 497.3427). 
 
(+) – 9b (tR HPLC = 8.4 min): white solid. 
 
m.p.:    80.6-81.8 °C. 
[α]D :    +27.2, (c = 4.514 g/100 mL, CHCl3) 
IR (CDCl3): 2932, 1086 cm
-1. 
¹H-NMR (C6D6, 400.13 MHz): 5.37 – 5.31 (1H, m), 5.01 – 4.97 (1H, m), 3.79 (1H, d, 
J=9.6 Hz), 3.64 – 3.50 (4H, m), 3.44 (1H, d, J = 9.6 Hz), 2.83 - 
2.79 (1H, m), 2.51 – 2.35 (3H, m), 2.16 – 1.98 (2H, m), 1.67 – 
1.35 (7H,, m),0.97 (3H, s), 0.95 – 0.68 (2H, m), 0.093 (3H, s), 
0.087 (3H, s). 
¹³C-NMR (C6D6, 100.61 MHz): 146.1, 113.5, 108.9 (CH2),  65.3 (CH2), 65.2 (CH2), 
64.7 (CH2),  49.7, 48.2 (CH), 47.6 (CH), 39.2, 38.6 , 36.0(CH2), 
35.8 (CH2),  31.9 (CH2), 31.3 (CH), 30.9 (CH2),  30.64 (CH), 
30.59 (CH2), 27.7 (CH3), 26.2 (3xCH3), 22.3 (CH2), 18.6 (CH2), 
16.1 (CH3), 15.9 (CH3), -5.25 (CH3), -5.29 (CH3). 
GC-MS: (tR 17.9) m/z = 474 [M
+] (7), 329 (14), 205 (9), 113 (100), 100 
(9), 89 (7), 73 (41), 69 (14), 55 (9). 
HRESIMS: m/z = 497.3423 (calcd for C29H50O3Si [M + Na]
+, 497.3427). 
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Synthesis of 10 from 9: 
 
H
TBDMSO H
OO
H
TBDMSO
O
H
OO
OsO4,THF
pyridine,H2O
NaIO4
yield  89%
9 10  
 
A solution of OsO4 (43 mg, 0.17 mmol),  pyridine (1.0 mL), and H2O (9 mL) was 
treated with a solution of  9 (4.1 g, 8.6 mmol) in THF (121 mL). After stirring in the 
dark for 10 min, the solution was treated with a suspension of NaIO4 (21 g, 98 mmol) in 
H2O (65 mL), and the resulting mixture stirred until TLC showed the disappearance of  
9 (92 h). The suspencion was filtered through Celite, the filtrate diluted with Et2O, and 
organic phase washed, dried, and evaporated. The residue was purified by CC (eluent: 
AcOEt/hexane = 1/9) to give 10 (3.7 g , 7.8 mmol) as a mixture of 10a and 10b (10a : 
10b, 1:9; Rf 10a > Rf 10b). 
 
(-) – 10a : white solid. 
 
m.p.:    141-142.3°C 
[α]D :    -2 (c = 1.89 g/100 mL, CHCl3)   
IR (CDCl3): 2932, 1773, 1094 cm
-1. 
¹H-NMR (C6D6, 400.13 MHz): 3.98 (1H, pq, J = 7.4 Hz), 3.76 (1H, td, Jd = 4.2 Hz, Jt = 
6.8 Hz), 3.66 – 3.57 (2H, m), 3.46 – 3.34 (2H, m), 3.03 (1H, d, J 
= 16.3 Hz), 3.00 (1H, d, J = 6.7 Hz), 2.54 (1H, dd, J = 6.7 Hz, J = 
16.3 Hz), 1.83 (1H, pd, J = 13.5 Hz), 1.71 – 1.51 (3H, m), 1.46 – 
1.04 (9H, m), 0.98 (9H, s), 0.97 (3H, s), 0.94 (3H, s), 0.81 (3H, s), 
0.78 – 0.64 (2H, m), 0.07 (3H, s), 0.06 (3H, s). 
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 ¹³C-NMR (C6D6, 100.61 MHz): 202.9, 110.1, 67.1(CH), 65.9(CH2), 65.1(CH2), 
65.0(CH2), 48.0(CH), 47.1 (CH2), 46.6, 40.6(CH), 40.2, 38.7, 
36.5(CH), 35.9 (CH2), 34.4 (CH2), 32.5(CH2), 30.5 (CH2), 
27.7(CH3), 26.2 (3xCH3), 23.0(CH2), 18.6, 18 .5(CH2), 17.1 
(CH3), 14.6 (CH3), -5.30 (CH3), -5.32 (CH3).     
GC-MS: (tR 21.1) m/z = 476 [M
+] (5), 207 (5), 147 (5), 134 (33), 119 (9), 
113 (37), 105 (8), 100 (6), 87 (100), 81 (9), 75 (51), 69 (12), 55 
(13). 
HRESIMS: m/z = 499.3241 (calcd for C28H48O4Si [M + Na]
+, 499.3220). 
 
(+) – 10b : white solid. 
 
m.p.:    101.6-103.0 °C. 
[α]D :    +34 (c = 2.908 g/100 mL, CHCl3) 
IR (CDCl3):   2936, 1771, 1088 cm
-1. 
¹H-NMR (C6D6, 400.13 MHz): 3.69 (1H, d, J = 9.6 Hz), 3.65 – 3.57 (1H, m), 3.54 – 
3.41 (3H, m), 3.39 (1H, d, J = 9.6 Hz), 3.04 – 2.99 (1H, m), 2.67 
(1H, A of ABX, JAB = 18.4 Hz, JAX = 4.6 Hz), 2.59 (1H, B of 
ABX, JAB = 18.4 Hz, JBX = 2.1 Hz), 2.22 – 2.09 (1H, m), 1.97 – 
1.78 (2H, m), 1.57 – 1.35 (3H, m), 1.33 – 1.06 (6H, m) 0.99 (9H, 
s), 0.98 (3H, s), 0.96 – 0.95 (1H, m), 0,94 (3H, d, J = 6.6 Hz), 
0.89 (3H, s) 0.74 (1H, td, Jd = 3.8 Hz, Jt = 13.6 Hz), 0.61(1H, qd, 
Jd = 4.2 Hz, Jq = 12.8 Hz), 0.07 (6H, s). 
¹³C-NMR (C6D6, 100.61 MHz): 204.8, 111.2, 65.2 (CH2), 65.00 (CH2), 64.0 (CH), 48.4 
(CH), 47.0 (CH2), 46.5, 39.2, 38.5, 35.8 (CH2), 35.1 (CH2), 33.9 
(CH), 31.6 (CH2), 31.3 (CH2), 30.1 (CH), 27.6 (CH3), 26.2 
(3xCH3), 22.3 (CH2), 18.6, 18.3 (CH2), 16.6 (CH3), 15.5 (CH3), -
5.30 (CH3), -5.34 (CH3). 
GC-MS: (tR 22.4) m/z = 476 [M
+] (1), 377 (4), 147 (6), 134 (29), 121 (5), 
113 (66), 105 (8), 100 (6), 93 (7), 87 (100), 81 (8), 75 (49), 69 
(11), 55 (11). 
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HRESIMS:  m/z = 499.3221 (calcd for C28H48O4Si [M + Na]
+, 499.3220). 
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Synthesis of 11 from 10: 
 
H
TBDMSO
O
H
OO
H
HO H
OH
O
1)NaBH4
Et2O/MeOH
2)THF, 2N HCl
yield 67%
10 11
endo / exo = 8 / 2  
 
A solution of 10 (1.2 g, 2.5 mmol) in Et2O/MeOH (1:1, 51 mL) was treated with 
NaBH4 (0.49 g, 13 mmol) at 0°C, and the mixture stirred until TLC showed the 
disappearance of 10 (20 min). H2O was added slowly at 0°C to quench excess NaBH4. 
After neutralization with 2N HCl the solution was diluted with Et2O, washed, dried, and 
evaporate, to give 1.2 g of crude. 
A solution of the crude (1.2 g) in THF/2N HCl (4:1; 210 mL) was refluxed for 7 h 
(until TLC showed the disappearance of it). After cooling to r.t., the whole was diluted 
with AcOEt, washed with saturated NaHCO3 and brine, dried, and evaporated. The 
residue was subjected to CC (AcOEt/hexane 3/7) to give 11 (0.72 g, 2.2 mmol, yield 
88%) as a mixture of 11a (endo) and 11b (exo) (11a:11b, 82:18; Rf 11a > Rf 11b), 
which for analytical purpose was separated by CC. 
 
(+) – 11a: white powder. 
 
m.p.:    191-192.3 °C 
[α]D :    +13.7(c = 2.842 g / 100 mL, CHCl3) 
IR (CDCl3):   2928, 1715 cm
-1. 
¹H-NMR (CDCl3, 400.13 MHz): 3.84 – 3.77 (2H, m), 3.44 (1H, d, J = 10.7 Hz), 2.61 
(1H, ddd, J = 3.0 Hz, J = 9.2 Hz, J = 14.1 Hz), 2.15 (1H, A of AB, 
JAB = 18.5 Hz,), 2.11 (1H, B of ABX, JAB = 18.5 Hz, JBX = 3.1 
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Hz), 1.91 – 1.61 (7H, m), 1.54 – 1.11 (8H, m), 0.99 (3H, s), 0.98 
(3H, s), 0.97 – 0.85 (5H, m). 
¹³C-NMR (CDCl3, 100.61 MHz): 216.0,74.1(CH), 65.5(CH2), 48.9, 47.5(CH), 
44.3(CH2), 43.4, 38.63, 38.58, 37.8 (CH2), 35.5 (CH2), 33.6(CH2), 
33.1 (CH2), 32.96(CH), 32.95 (CH2), 27.6(CH3), 22.1 (CH2), 18.5 
(CH2), 17.4 (CH3), 16.1 (CH3). 
GC-MS: (tR 16.4) m/z = 320 [M
+] (5), 289 (25), 276 (25), 260 (32), 253 
(11), 245 (13), 229 (17), 207 (11), 173 (11), 161 (21), 147 (26), 
145 (20), 137 (15), 136 (13), 135 (38), 123 (93), 105 (73), 91 
(65), 81 (96), 67 (70), 55 (100). 
HRESIMS: m/z = 343.2232  (calcd for C20H32O3Si [M + Na]
+, 343.2249). 
 
(-) – 11a: white powder. 
 
m.p.:    184.5-186.5 °C 
[α]D :     +37.1 (c = 2.455 g / 100 mL, CHCl3) 
IR (CDCl3):  2934, 1715 cm
-1. 
¹H-NMR (CDCl3, 400.13 MHz): 3.81 (1H, d, J = 10.8 Hz), 3.74 – 3.67 (1H, m), 3.45 
(1H, d, J = 10.8 Hz), 2.14 – 1.79 (6H, m), 1.77 – 1.22 (13H, m), 
0.98 (3H, s), 0.96 (3H, s), 0.93 – 0.84 (4H, m). 
 ¹³C-NMR (CDCl3, 100.61 MHz): 216.9, 70.5(CH), 65.5(CH2), 49.1, 47.2(CH), 
44.3(CH2), 42.4, 38.7, 38.6, 35.5 (CH2), 33.2 (CH2), 33.1 (CH), 
32.6 (CH2), 31.8 (CH2), 31.6 (CH2), 27.5 (CH3), 22.2 (CH2), 18.5 
(CH2), 17.1 (CH3), 15.9 (CH3). 
GC-MS: (tR 16.1) m/z = 320 [M
+] (6), 289 (24), 276 (13), 271 (30), 229 
(19), 173 (10), 159  (20), 147 (27), 135 (19), 123 (100), 121 (33),  
105 (52), 91 (48), 81 (67), 69 (40), 55 (71). 
HRESIMS: m/z = 343.2256  (calcd for C20H32O3Si [M + Na]
+, 343.2249). 
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Synthesis of 12 from 11: 
 
H
HO H
OH
O
H
HO H
O
TsOH,
toluene
80°C
yield 74%
11 12
endo / eso = 8 / 2  
 
A solution of 11 (11a+11b, 0.35 g, 1.1 mmol) and TsOH (0.19 g, 1.0 mmol) in 
toluene (54 mL) was heated at 85°C until TLC showed the disappearance of 11 (48 h). 
After cooling to r.t., the whole was diluted with AcOEt, washed with satured NaHCO3, 
brine, dried, and evaporated.  
The residue was purified by CC (eluent: AcOEt/hexane 1:9) to give 12 (0.22 g, 0.73 
mmol, 66%) as a white powder. 
 
m.p.:    165.1 – 166.8°C 
[α]D :    +539 (c = 2.7 g / 100 mL, CHCl3) 
IR (CDCl3):  2936, 1728, 1213 cm
-1. 
¹H-NMR (C6D6, 400.13 MHz): 5.10 (1H, d, J = 2.8 Hz), 3.53 (1H, d, J = 10.4 Hz), 3.15 
(1H, d, J = 10.4 Hz), 2.51 (1H, bs), 2.06 (1H, d, J = 18.3 Hz), 1.95 
– 1.76 (3H, m), 1.65 (3H, s), 1.61 – 1.53 (1H, m), 1.49 – 0.94 
(10H, m), 0.91 (3H, s), 0.81 (1H, bs), 0.74 (1H, td, Jd = 3.9 Hz, Jt 
=13.4 Hz), 0.64 (3H, s). 
 ¹³C-NMR (C6D6, 100.61 MHz): 207.9, 131.5, 128.5 (CH),  64.8(CH2), 55.5 (CH),, 
48.5(CH), 48.0,  44.0 (CH2), 42.2(CH), 38.74, 38.66, 35.5 (CH2), 
32.6 (CH2), 32.2 (CH2),  27.5 (CH3), 26.3 (CH2), 22.3(CH2), 21.7 
(CH3), 18.5 (CH2), 18.1 (CH3). 
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GC-MS: (tR 13.4) m/z = 302 [ M
+] (24), 284 (14), 271 (16), 229 (14), 161 
(14), 157 (11), 147 (26), 131 (28), 119 (52), 105 (100), 91 (79), 81 
(56), 67 (43), 55 (59). 
HRESIMS: m/z = 325.2152  (calcd for C20H30O2Si [M + Na]
+, 325.2144). 
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Synthesis of 13 from 12: 
 
H
HO H
O
H
HO H
1)BF3Et2O
2)HSCH2CH2SH
yield 84%
12 13
SS
 
 
To a solution of 12 (0.18 g, 0.60 mmol) in 1,2-ethanedithiol (1.1 mL, 13 mmol), 
cooled to 0°C, was added BF3∙Et2O ( 0.47 mL, 3.8 mmol) while stirring until TLC 
showed the disappearance of 12(10 min). The mixture was diluted with CH2Cl2 (30 
mL), washed with 2N NaOH (3 x 6 mL), H2O until neutral, brine, dried, and 
evaporated. The mixture was purified by CC (eluent: AcOEt/hexane 93/7) to give 13 
(191 mg, 0.5 mmol): white powder. 
 
m.p.:    171.7 – 173.4°C 
[α]D :    +105 (c = 3.2 g /100 mL, CHCl3) 
IR (CDCl3):  2965 cm
-1. 
¹H-NMR (CDCl3, 400.13 MHz): 5.11 (1H, pd, J = 2.0 Hz), 3.77 (1H, d, J = 10.8 Hz), 
3.39 (1H, d, J = 10.8 Hz), 3.37 – 3.15 (4H, m), 2.47 (1H, d, J = 
14.6 Hz), 2.33 (1H, d, J = 3.8 Hz), 2.13 – 2.05 (1H, m), 2.01 (1H, 
dd, J = 3.8 Hz, J = 11.6 Hz), 1.71 – 1.28 (8H, m), 1.25 – 1.11 (2H, 
m), 0.97 – 0.85 (7H, m). 
¹³C-NMR (CDCl3, 100.61 MHz): 137.3, 128.6 (CH), 76.5,  65.4 (CH2), 56.2 (CH), 
50.57, 50.47 (CH2),  49.5(CH),  44.5 (CH), 40.1 (CH2),  39.3 
(CH2), 38.65, 38.63, 35.4 (CH2), 32.6 (CH2), 31.3 (CH2),  30.2 
(CH2), 27.1 (CH3), 24.5 (CH3), 22.0(CH2), 18.2 (CH2), 17.8 
(CH3). 
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GC-MS: (tR 23.2) m/z = 378 [M
+] (14), 260 (16), 210 (8), 182 (11), 157 (11), 
144 (22), 131 (21), 119 (32), 105 (100), 91 (41), 81 (24), 67 (20), 
55 (32). 
HRESIMS: m/z = 401.1961  (calcd for C22H34O2Si [M + Na]
+, 401.1949).   
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Synthesis of 14 from 13: 
 
H
OH H
H
HO H
Ni-Raney,
EtOH
60°C
yield 62%
(+)-2-deoxyoryzalexin S
113
SS
 
 
A solution of 13 (0.17 g, o.44 mmol) in EtOH (58 mL) was stirred at 60°C with 
Raney-Ni until TLC showed the disappearance of 13 (30 min). The catalyst was 
removed by filtration through Celite, the solvent evaporated, and the mixture purified 
by CC (eluent: AcOEt/hexane 5:95) to give 1 (79 mg, 0.27 mmol): white solid. 
 
 m.p.:    116.1 – 117.6°C 
[α]D :    +58 (c = 1.8 g /100 mL, CHCl3) 
IR (CDCl3):  2965 cm
-1. 
¹H-NMR (CDCl3, 400.13 MHz): 4.94 (1H, pd, J = 4.3 Hz), 3.80 (1H, d, J = 10.9 Hz), 
3.41 (1H, dd, J = 1.0 Hz, J = 10.9 Hz), 2.19 (1H, t, J = 4.4 Hz), 
2.01 – 1.93 (1H, m), 1.87- 1.79 (1H, m), 1.75 – 1.10 (19H, m), 
0.98 – 0.85 (7H, m). 
¹³C-NMR (CDCl3, 100.61 MHz): 138.9, 123.9 (CH),  65.5 (CH2), 51.1, 50.2 (CH), 44.4 
(CH), 43.3 (CH), 38.8, 38.7, 35.6 (CH2), 33.4 (CH2), 32.4 (CH2),  
32.0 (CH2),  31.8 (CH2),  30.0 (CH2), 27.7 (CH3), 22.12 (CH3), 
22.09 (CH2),  18.4 (CH2), 17.9 (CH3).    
GC-MS: (tR 11) m/z = 288 [M
+] (20), 257 (54), 229 (8), 201 (8), 187 (20), 
175(15), 161 (33), 145 (33), 131 (59), 119 (43), 105 (100),  91 
(78), 81 (72), 67 (47), 55 (77). 
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HRESIMS: m/z = 311.2353  (calcd for C20H32O [M + 
Na]+, 311.2351).  
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Synthesis of 17 from 11a: 
 
OH
HO
H
H
OH
HO
H
H
S
S
BF3.Et2O
HSCH2CH2SH
0 °C
O
yield 59%
11a 17  
 
To a solution of 11a  (0.164 g, 0.51 mmoli) in 1,2-ethanedithiol (0.97 ml, 11.6 
mmoli), cooled to 0°C, was added BF3∙Et2O (0.39 mL, 3.17 mmol) while stirring until 
TLC (AcOEt/hesane = 5/5)  showed the disappearance of  the starting material.  
The mixture was diluted with CH2Cl2 , washed with 2N NaOH, H2O until neutral, 
brine, dried, and evaporated. The mixture was purified by CC (AcOEt/hexane 15/85) to 
give 17 (0.120 g, 0.3 mmol, yield 59%) as a white powder. 
 
m.p.:    161.6-163.2 °C 
 [α]D :    2.7 (c = 4.03 g / 100 mL, CHCl3) 
IR (CHCl3): 3684, 3628, 3018, 2935, 2399 cm
-1. 
¹H-NMR (CDCl3): 0.72-0.76 (m, 1H), 0.90 (s, 3H), 0.97 (s, 3H), 1.34 (s,   3H),1.17-
1.93 (m,   13H), 1.98-2.0 (d, 3H), 2.32-2.33 (d, 2H), 2.40-2.46 (m, 
1H), 3.14-3.24 (m, 3H), 3.34-3.37 (m, 1H), 3.42-3.44 (d, 1H), 
3.69-3.72 (m, 1H), 3.79-3.82 (d, 1H). 
¹³C-NMR (CDCl3): 75.3, 72.6, 65.5, 51.1, 47.7, 41.8, 41.7, 41.5, 41.2, 38.5,   37.7, 
35.5, 34.1, 33.1, 33.0, 32.8, 27.5, 22.2, 19.9, 18.4, 17.0. 
HPLC:  (eluent: AcOEt/hexane = 35/65), flow (1ml/min), tr 6.1 min.
 
EXPERIMENTAL PART 
 
122 
 
Synthesis of 18 from 17: 
 
OH
HO
H
H
S
S
OH
HO
H
H
Raney-Ni
abs. EtOH
60 °C
yield 67%
17 18  
 
A solution of 17 (0.123 g, 0.31 mmoli) in abs. EtOH (42.1 mL) was stirred at 60°C 
with Raney-Ni until TLC ( AcOEt/hesane  4/6) showed the disappearance of 13 (3h). 
After cooling,  the catalyst was removed by filtration through Celite, the solvent 
evaporated, and the mixture purified by CC (eluent: AcOEt/hexane 20/80) to give 18 
(64 mg, 0.21 mmol, yield 67%): white solid. 
 
  
m.p.:   167.8-168.5 °C 
[α]D :    -18 (c = 2.997 g / 100 mL, CH2Cl2) 
IR (CHCl3): 3684, 3620, 3018, 2937, 2399 
¹H-NMR (CDCl3): 0.67-0.71 (m, 1H), 0.78 (s, 3H), 0.92 (s, 3H), 0.97 (s,3H),    1.05-
1.89 (m, 20H), 2.37-2.43 (m, 1H), 3.33-3.35 (d, 1H), 3.47-3.51 
(m, 1H), 3.81-3.83 (d, 1H). 
¹³C-NMR (CDCl3):  73.2, 63.8, 41.19, 39.5, 38.6, 38.2, 35.3, 33.8, 33.77, 3.73, 32.7, 
32.2, 26.8, 26.3, 25.5, 22.6, 22.0, 18.1, 15.7. 
GC-MS: (tR 13.3) m/z = 306 (M
+, 0.31), 288 (6), 275 (32), 257 (36), 245 
(4), 229 (3), 215 (4), 201 (6), 187 (9), 175 (10), 161 (15), 147 
(15), 133 (21), 123 (61), 105 (52), 91 (59), 81 (100), 67 (67), 55 
(92).  
HPLC: (eluent AcOEt/hexane = 35/65), flow (1ml/min), tR 2.47 min.
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Synthesis of 19 from 18: 
 
OH
HO
H
H HO
H
H
TsOH, anh. benzene
48h, 80°C
yield 60%
19
18
 
 
A solution of 18 (0.0458 g, 0.149 mmol) and TsOH (0.00141 g, 7.45∙10-3 mmol) in 
anh. benzene (5.4 mL) was heated at 80°C (4h). After cooling to r.t., the reaction 
mixture was diluted with AcOEt, washed with satured NaHCO3, brine, dried, and 
evaporated.  
The residue was first purified by CC (SiO2; AcOEt/hexane 5:95) and then by 
semipreparative HPLC (Nucleodur; AcOEt/hesane  5/95) because after chromatography 
the GC-MS showed the presence of two compounds. 
After semipreparative HPLC, 19 (0.0076 g, 2.64∙10-2 mmol, 17.7%) was obtained. 
 
 
¹H-NMR (CDCl3): 1.01-1.02 (d, 6H), 1.10-2.18 (m, 22H), 2.38-2.42 (d, 1H), 3.52-
3.55 (d, 1H), 3.90-3.93 (d, 1H), 5.05 (s, 1H). 
¹³C-NMR (CDCl3): 142.1, 117.0, 65.8, 50.8, 48.5, 46.8, 42.9, 38.4, 38.0, 37.3,  35.6, 
35.2, 32.5, 31.7, 29.5, 27.6, 22.1, 21.3, 20.7, 18.4. 
GC-MS: (tR 11.06) m/z = 288 (M
+, 18), 273 (11), 257 (47), 241 (1), 231 
(10), 213 (5), 206 (13), 187 (11), 175 (15), 163 (28), 147 (25), 
133 (31), 119 (37), 105 (75), 91 (94), 81 (99), 67 (68), 55 (100). 
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Synthesis of Methyl abietate 22 from abietic acid 21: 
 
H
H
HO2C
H
H
MeO2C
21 22
LiOH, DMF
Me2SO4
abietic acid
yield 98%
 
 
A solution of abietic acid 21 (20 g, 0.066 mol), and lithium hydroxide monohydrate 
(6 g, 0.132 mol) in dimethylformamide (80 mL) was stirred for 4h at r.t. and then 
cooled by means of a ice-water bath. After addition of dimethyl sulphate (20 mL) 
stirring was continued for 15 min. The mixture was poured into water and extracted 
with hexane.  
The combined extracts were washed with 5% HCl solution, 10% NaHCO3 solution 
and brine. After drying and concentration in vacuo 20,47 g (0,065 mol, 98%) of methyl 
abietate 22, as an oil, was obtained. 
 
IR (KBr): 1722 cm-1 
¹H-NMR (CDCl3, 400.13 MHz ): 5.76 (s, 1H); 5.35 (d,1H); 3.61 (s, 3H); 2.29-1.48 (m, 
10H); 1.24 (s,3H); 1.02-0.96 (m, 6H); 0.81 (s,3H). 
¹³C-NMR (CDCl3, 400.13 MHz ): 179.1, 145.4, 135.7, 122.5, 120.7, 51.9, 51.1, 46.7, 
45.2, 38.5, 37.2, 35.0, 34.7, 27.6, 25.8, 22.6, 21.5, 20.9, 18.2, 
17.1, 14.1. 
GC-MS: (tR 11.14) m/z = 316 (M
+, 50), 281 (3), 273 (7), 256 (100), 241 
(68), 213 (64), 213 (6), 185 (54), 157 (14), 143 (29), 131 (56), 
121 (91), 105 (87), 91 (82), 79 (52), 67 (43), 55 (66). 
 
EXPERIMENTAL PART 
125 
 
Synthesis of 23 from 22: 
 
H
H
MeO2C
22
HBr,
Acetic acid
H
H
MeO2C
Br
Br
23  
 
A solution of methyl abietate 22 (5 g, 0.016 mmol) in acetic acid (15 mL) was added 
to a solution of 33% HBr in acetic acid (15 mL) and stirred for 6 h at r.t. 
The precipitated solid was collected by vacuum filtration, the filtrate separated, and 
the solid washed with acetic acid and water. After drying in vacuo over P2O5, 3.21 g 
(6.72x10-3 mmol, yield 42%) of the compound 23 was obtained. 
  
m.p.:    146- 148 °C (lit. 148 °C) 
IR (KBr): 1722 cm-1 
¹H-NMR (CDCl3, 400.13 MHz ): 3.66 (s, 3H); 2.40-2.27 (m, 2H); 2.15-1.78 (m, 7H); 
1.76 (s, 6H); 1.62-1.44 (m, 5H); 1.35-1.20 (m, 2H); 1.18 (s,3H); 
1.15-1.10 (m, 1H); 1.05 (s, 3H);  0.95-0.79 (m, 2H). 
¹³C-NMR (CDCl3, 400.13 MHz ): 179.3, 77.9, 73.0, 59.6, 52.1, 50.7,48.3, 46.9, 46.2, 
38.9, 37.0, 33.1, 32.9, 28.9, 22.5, 22.1, 17.6, 16.7, 16.5. 
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Synthesis of 24 from 23: 
 
H
H
MeO2C
Br
Br
23
LiOH, DMF
H
MeO2C
24
yield 72%
 
 
An intimate mixture of 23 (5 g, 10.4 mmol) and powdered lithium hydroxide 
monohydrate (0.9 g) in dimethylformamide (40 mL) was stirred while the temperature 
was raised over 30 min. to 80°C. The resulting solution was stirred for 3 h and 30 min at 
the same temperature and the reaction mixture was then poured into water and extracted 
with hexane. The hexane extract was washed with 5% HCl solution, 10% NaHCO3 
solution and brine. 
The white residue obtained after drying, was then crystallized from methanol to give 
24 (2.4 g, 7.5 mmol, yield 72%). 
 
 
m.p.:    104 – 105°C (lit. 104.5-106 °C) 
IR (CHCl3): 1720 cm
-1. 
¹H-NMR (CDCl3): 3.65 (s, 3H); 2.77-2.32 (m, 2H); 2.15-1.47 (m, 18H); 1.18 (s, 3H); 
0.96 (m, 3H). 
¹³C-NMR (CDCl3): 16.5, 18.3, 19.5, 19.7, 20.2, 21.7, 24.9, 27.6, 31.8, 34.8, 35.4, 
36.8, 37.2, 46.5, 47.8, 51.9, 120.8, 126.2, 128.4, 138.3, 179.4.   
GC-MS: (tR =11.09) m/z = 316 (M
+, 25), 301 (10), 269 (2), 257 (6), 241 
(29), 237 (4), 213 (6), 199 (3), 181 (10), 159 (12), 148 (35), 135 
(100), 121 (39), 105 (29), 91 (37), 79 (22), 67 (17), 55 (31). 
. 
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Synthesis of 25 from 24: 
 
H
MeO2C
24
yield 48%
1) O3, CH2Cl2,
-78°C
2) Zn, CH3COOH
O
H
MeO2C
25  
 
In a three neck flask, under magnetic stirring, a stream of ozone was passed for 
approximately 20 min at -78°C through a solution of 24 (1 g, 3.16 mmol) in 
dicloromethane (50 mL).  
After 30 min, the excess ozone was removed with a stream of Argon. The mixture 
was then treated with Zinc powder (2.1 g) and acetic acid (3 mL) and removed from the 
cooling bath. The resulting mixture was stirred at r.t. for 30 min.  The reaction mixture 
was filtered with dicloromethane on Celite to remove the excess of zinc powder 
The combined extracts were washed with satured solution NaHCO3, water until 
neutrality, brine,  dryied on Na2SO4, concentrated and chromatographed on silica gel 
(hexane/ether = 9/1). 
After chromatographic separation 25 (0.44 g, 1.52 mmol, yield 48%) was obtained.  
 
m.p.:    108-110°C 
[α]D :    +157 (c = 1.81 g/100 ml, CHCl3) 
IR (CHCl3): 1715 cm
-1. 
¹H-NMR (CDCl3): 3.66 (s, 3H); 2.69 (m, 2H); 2.52-2.24 (m, 9H); 1.33-1.12 (m, 4H); 
1.04 (m, 3H). 
¹³C-NMR (CDCl3): 16.5, 18.1, 19.7, 21.3, 23.8, 31.3, 35.4, 36.7, 37.4, 39.4, 44.6, 
46.3, 47.6, 49.8, 52, 124.9, 139.1, 179.1, 179.6, 211.5.   
GC-MS: (tR =10.63) m/z = 290 (M
+, 29), 275 (19), 231 (31), 215 (100), 
197 (20), 173 (44), 159 (48), 149 (24), 131 (20), 121 (24), 105 
(41), 91 (58), 79 (42), 67 (22), 55 (58).  
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Synthesis of 26 from 25: 
 
O
H
MeO2C
25
O
H
MeO2C
26
HCl, MeOH
Hyield 88%
 
 
A solution of 25 (1 g, 3.44 mmol) and conc. HCl (26 mL) in methanol (10 mL) was 
refluxed, under Argon, for 40 min. The reaction mixture was diluited with water and 
extracted with Et2O.  
The organic phase was washed with satured solution NaHCO3, brine, dried on 
Na2SO4, concentrated in vacuum and chromatographed on silica gel (hexane/ether = 
8/2). 
After chromatographic separation 26 (0.88 g, 3.03 mmol, yield 88%) was obtained.  
 
 
m.p.:    125-127°C. 
[α]D :    +30 (c = 1.15 g/100 ml, CHCl3) 
IR (CHCl3):  1720, 1660, 1615 cm
-1. 
¹H-NMR (CDCl3, 400.13 MHz): 5.86 (s,1H); 3.67 (s,3H); 2.56-1.92 (m, 6H); 1.86-1.45 
(m, 6H); 1.39-1.11 (m, 4H); 0.83 (s, 3H). 
¹³C-NMR (CDCl3, 400.13 MHz): 15.7, 17.1, 18, 20.4, 24.2, 35.3, 36.8, 37, 38.4, 47.4, 
48.3, 48.2, 51.7, 52.2 126.3, 164.5, 179, 199.6. 
GC-MS:  (tR =11.71) m/z = 290 (M
+, 5), 275 (1), 258 (0.4), 231 (9), 215 (5), 
197 (1), 181 (13), 159 (6), 149 (2), 135 (4), 121 (50), 110 (100), 
91 (16), 79 (16), 67 (12), 55 (21). 
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Synthesis of 27 from 26: 
 
O
H
MeO2C
26
H
Allene, -78°C
THF, hv
O
H
MeO2C
27
H
yield 67%
 
 
 
A Pyrex vessel containing a solution of 26 (6.9 g, 23.7 mmol) in THF (78 mL) was 
cooled at -78°C, and an excess of allene was condensed into it. The vessel was 
irradiated under Ar at -78°C with a 500 W mercury vapor lamp until TLC (Et2O/hexane 
= 4/6)  showed the disappearance of 26. 
The reaction vessel was then removed from the cooling bath and kept overnight 
under the fumehood to allow the unreacted allene to evolve. Evaporation of the organic 
solvent gave a residue which was purified by CC (SiO2; petroleum ether(40°-70°)/Et2O 
= 7/3).  
After chromatographic separation 27 (5.26 g, 15.9 mmol, yield 67%) was obtained. 
 
m.p.:    97.7 – 98.8 °C 
IR (CCl4):  1715 cm
-1. 
¹H-NMR (CDCl3): 0.77 (s, 3H); 1.09 (s, 3H); 3.59 (s, 3H); 4.84 (m, 1H); 4.92 (m, 
1H).  
¹³C-NMR (CDCl3): 14.9, 16.2 (C(19), C(20)); 17.2, 18.2, 21.6 (C(2), C(6), C(11)); 
36.6, 37.5, 37.6, 37.9, 39.5, 39.9, 40.4 (C(1), C(3), C(7), C(8), 
C(10), C(12), C(16)); 47.4 (C(4); 50.2, 51.8, 53.7 (C(5), C(9), 
(MeO)); 62.9 (C(14)); 110.0 (=CH2); 142.1 (C(15)); 179.2 
(C(18)); 210.5 (C(13)). 
EI-MS: 330 (23, M+). Anal. calc. for C21H30O3 (330.47): C 76.33, H 9.15; 
found C 76.22, H 9.17. 
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Synthesis of 28 from 27: 
 
O
H
MeO2C
27
H
OHHO
TsOH
H
MeO2C
28
H
O
O
yield 95%
 
 
To a solution of 27 (0.501 g, 1.51 mmol) in anh. benzene (80 mL) an excess of 
ethylenglycol and catal. amount of  TsOH were added; the mixture was refluxed under 
N2 with azeotropic removal of water (Dean-Stark trap), until TLC (petroleum ether 
(40°-70°)/EtO2 7/3) indicated the complete disappearance of the starting material. The 
mixture was then cooled to r.t., diluited with ether, washed with NaHCO3 solution, 
water (till neutral), brine, dried on Na2SO4, and evaporated.  
The residue was purified by CC (SiO2; petroleum ether (40°-70°)/EtO2 9/1) and after 
chromatographic separation, 28 (0.539 g, 1.44 mmol, yield 95%) was obtained. 
 
m.p.:    81.2 – 83.1°C 
IR (CCl4): 1718 cm
-1. 
¹H-NMR (CDCl3): 0.75 (s, 3H); 1.10 (s, 3H); 3.60 (s, 3H); 3.80-4.00 (m, 4H); 4.83 
(m, 1H); 4.94 (m, 1H). 
¹³C-NMR (CDCl3):  14.1, 16.4 (C(19), C(20)); 17.3, 17.5, 21.9 (C(2), C(6), C(11)); 
28.6 (C(12)); 36.7, 37.3, 37.5, 38.0, 38.9, 41.0 (C(1), C(3), C(7), 
C(8), C(10), C(16)); 47.4 (C(4)); 48.0, 50.2, 51.7 (C(5), C(9), 
(MeO)); 51.7 (C(14)); 64.1, 64.3 (OCH2CH2O); 109.8, 110.4 
(C(13), (=CH2)); 145.9 (C(15)); 179.5 (C(18)). 
EI-MS: 374 (100, M+). Anal. calc. for C23H34O4 (374.52): C 73.76, H 
9.15; found C 73.59, H 9.20. 
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Synthesis of 29 from 28: 
 
H
MeO2C
28
H
O
O
OsO2, NaIO4
H
MeO2C
29
H
O
O
O
yield 76%
 
 
A solution of  OsO4 (20 mg,) in THF (2 mL) was added to a solution of 28 (103 mg, 
0.27 mmol) in dioxane (5 mL). After stirring in the dark for 15 min, water (1 mL) and 
pyridine (1 mL) were added. A solution af NaIO4 (235 mg, 1.10 mmol) in water (10 
mL) was then added dropwise. The mixture was stirred in the dark for 45 h. The 
mixture was then filtered under reduced pressure through a Celite pad, and the filter and 
the flask were washed with methanol. The organic solvent was then evaporated and the 
residue taken up with water and extracted with Et2O. 
The combined organic extracts were then washed with NaHCO3 solution, water (till 
neutral), brine, dried on Na2SO4, and evaporated.  
The residue was purified by CC (SiO2; petroleum ether (40°-70°)/EtO2 9/1) and after 
chromatographic separation 28 (77 mg, 0.20 mmol, yield 76%) was obtained. 
 
m.p.:    155.6 – 156.1°C 
IR (CCl4):  1725, 1782 cm
-1. 
¹H-NMR (CDCl3): 0.75 (s, 3H); 1.11 (s, 3H); 2.33 (dd, J = 6.5, J =16.3, 1H); 2.69 
(dd, J = 2, J = 6.5, 1H); 3.34 (d, J = 16.3, 2H); 3.61 (s, 3H); 3.70-
4.00 (m,4H). 
¹³C-NMR (CDCl3): 14.6, 16.1 (C(19), C(20)); 17.4, 17.4, 22.0 (C(2), C(6), C(11)); 
34.5, 34.6, 36.7,  37.5, 37.5, 40.6 (C(1), C(3), C(7), C(8), C(10), 
C(12)); 47.3 (C(4)); 50.3, 51.2, 51.8 (C(5), C(9), (MeO)); 52.2 
(C(16)); 64.3, 64.9 (OCH2CH2O);73.1 (C(14)); 107.3 (C(13)); 
179.3 (C(18)); 205.8 (C(15)). 
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EI-MS: 376 (19, M+). Anal. calc. for C22H32O5 (376.49): C70.19, H 8.57; 
found C 70.23, H 8.59. 
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Synthesis of 31 from 29: 
 
H
MeO2C
31
H
2) THF, 2N HCl
reflux 24 h
yield 85%
1) NaBH4,
MeOH/Et2O
H
MeO2C
29
H
O
O
O
OH
O
 
 
To a stirred solution of 29 (67 mg, 0.18 mmol) in a 1:1 MeOH/Et2O mixture (5 mL), 
NaBH4 was added. When TLC (petroleum ether (40°-70°)/Et2O 1/1, Rf (30) < Rf (29)) 
indicated the complete disappearance of 29, the solution was evaporated and the residue 
taken up with water and extracted with CHCl3. 
The combined organic extracts were then washed with water (till neutral), brine, 
dried on Na2SO4, and evaporated. The crude product 30 could be used in the subsequent 
reaction without purification. 
A solution of 30 dissolved in 2:1 THF/2N HCl (7.5 mL) was refluxed under N2 for 
24h. After neutralization (4N NaOH) and evaporation of the organic solvent, the residue 
was taken up with water and extracted with Et2O. The combined organic extracts were 
then washed with water, brine, dried on Na2SO4, and evaporated.  
The residue was purified by CC (SiO2; petroleum ether (40°-70°)/EtO2 1/1) gave 31a 
(endo -OH) and 31b (exo -OH) in a 76.6% and 8.3% yield, respectively. TLC 
(petroleum ether (40°-70°)/EtO2 2/8): Rf (31a) < Rf (31b). 
  
Data of 31a (endo -OH) 
 
m.p.:    221.2 – 223.2°C 
IR (CCl4):  1705, 1720, 3400 cm
-1. 
¹H-NMR (CDCl3): 0.94 (s, 3H); 1.15 (s,3H); 3.63 (s,3H); 4.12 (m,1H). 
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¹³C-NMR (CDCl3):  14.5, 16.3 (C(19), C(20)); 16.9, 21.0, 21.9 (C(2), C(6), C(11)); 
36.4, 36.6, 37.0,  37.5, 38.3, 39.1 (C(1), C(3), C(7), C(8), C(10), 
C(14)); 47.1 (C(4)); 50.2,  50.3, 51.5, 51.9 (C(5), C(9), C(12), 
(MeO)); 55.1 (C(15)); 69.1 (C(13)); 179.4 (C(18)); 215.3 (C(16)). 
EI-MS: 334 (25, M+). Anal. calc. for C20H30O4 (334.45): C70.82, H 9.04; found 
C 71.92, H 9.03.  
 
Data of 31b (exo -OH) 
 
m.p.:    186.7- 187.8°C 
IR (CCl4):  1710,1720, 3420 cm
-1. 
¹H-NMR (CDCl3):  1.10 (s, 3H); 1.13 (s,3H); 3.61 (s,3H); 4.20 (m,1H). 
¹³C-NMR (CDCl3): 15.4, 16.3 (C(19), C(20)); 17.0, 17.5, 21.1 (C(2), C(6), C(11)); 
36.3, 36.7, 37.4,  38.1, 38.3, 38.5 (C(1), C(3), C(7), C(8), C(10), 
C(14)); 47.2 (C(4)); 50.1,  51.8, 51.8, 52.2 (C(5), C(9), C(12), 
(MeO)); 54.7 (C(15)); 65.8 (C(13)); 179.5 (C(18)); 215.5 (C(16)). 
EI-MS: 334 (4, M+). Anal. calc. for C20H30O4 (334.45): C71.82, H 9.04; found C 
71.89, H 9.03. 
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